WO1999045935A1 - Novel nucleoside analogs and uses in treating disease - Google Patents

Novel nucleoside analogs and uses in treating disease Download PDF

Info

Publication number
WO1999045935A1
WO1999045935A1 PCT/US1999/005360 US9905360W WO9945935A1 WO 1999045935 A1 WO1999045935 A1 WO 1999045935A1 US 9905360 W US9905360 W US 9905360W WO 9945935 A1 WO9945935 A1 WO 9945935A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
oriented
fluoro
evaporated
deoxyuridine
Prior art date
Application number
PCT/US1999/005360
Other languages
French (fr)
Inventor
Alexander L. Weis
Kirupathevy Pulenthiran
Annette M. Gero
Original Assignee
Lipitek International, Inc.
Unisearch Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/038,647 external-priority patent/US5939402A/en
Application filed by Lipitek International, Inc., Unisearch Limited filed Critical Lipitek International, Inc.
Priority to JP2000535350A priority Critical patent/JP2002506036A/en
Priority to EP99912434A priority patent/EP1069903A1/en
Priority to CA002322494A priority patent/CA2322494A1/en
Priority to AU30808/99A priority patent/AU3080899A/en
Publication of WO1999045935A1 publication Critical patent/WO1999045935A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention relates to novel nucleosides and dinucleoside dimers and derivatives of these compounds, including, L-deoxyribofuranosyl nucleoside phosphodiester dimers in which the sugar moiety of at least one of the nucleosides has an L-configuration.
  • These compounds are highly effective in the treatment of various diseases. They may be used to treat parasitic infections such as the one caused by Plasmodium falciparum, the etiologic agent responsible for the most fatal form of malaria. They may also be used to treat bacterial, viral, and fungal infections, and may also be used to treat cancer.
  • Modified nucleoside analogs are an important class of antineoplastic and antiviral drugs.
  • the present application discloses novel compounds for of this type for use in the treatment of P. falciparum infection and other parasitic infections.
  • Plasmodium falciparum is the etiologic agent responsible for the most fatal form of malaria, a disease which afflicts between 200 and 300 million people per year (all forms), including over one million childhood deaths. Additionally, greater than 40% of the world's population lives in areas in which malaria is at epidemic levels. Due to the extraordinary morbidity and mortality associated with malaria and other parasitic infections, related research has intensified during the past decade in a desperate search for effective treatments. Safe and effective vaccines still do not exist. Instead, many victims must depend upon chemotherapy.
  • modified nucleoside analogs may also be used to treat various other parasitic infections, bacterial infections, fungal infections, viral infections, and cancer.
  • chemotherapeutic agents can be classified into two groups: those that act post-translationally, and those that act by interfering with nucleic acid synthesis.
  • Most drugs are in the first group, which means that they exert their therapeutic effect by interfering with a cell's protein synthesis, and hence its metabolism (rather than its nucleic acid synthesis).
  • Examples of drugs in this group include: the antifolate compounds (which inhibit dihyrdofolate reductase), and sulfonamide drugs (which inhibit dihydropteroate synthetase.
  • drugs in this group include: the antifolate compounds (which inhibit dihyrdofolate reductase), and sulfonamide drugs (which inhibit dihydropteroate synthetase.
  • the protozoan responsible for malaria very quickly develops resistance to these drugs. The reason is that, since resistance occurs through adaptive mutations in successive generations of the parasite, a one or two point mutation is often sufficient to confer resistance. Bacterial,
  • the second group of compounds includes the nucleic acid intercalators such as acridines, phenanthrenes and quinolines. These intercalators partially mimic the biochemical activity of nucleic acids, and therefore are incorporated into the protozoan's, or a cell's, nucleic acid (DNA and RNA), though once incorporated, do not allow further nucleic acid synthesis, hence their effectiveness. At the same time, these intercalators interfere with host nucleic acid synthesis as well, and thus give rise to toxic side effects. Because of the potential for toxic side effects, these drugs can quite often be given only in very small doses. Once again, a resistance pattern may develop. For example, a number of protozoans are known to develop "cross-resistance,” which means that the parasites develop resistance to other classes of drugs even though they were exposed to a different class of drug.
  • L-nucleosides may be used as highly selective drugs against parasite infection, or against any other type of cell or organism utilizing the L-nucleosides.
  • the chemical modification of the L-nucleosides consists generally of modifying the nucleosides so that they are still recognized by the invading cell or organism's nucleic acid synthetic machinery, and therefore incorporated into a nucleic acid chain, but yet once this incorporation occurs, no further synthesis will take place.
  • dimers of these nucleoside analogs are well known, dimers in which one or both nucleosides are of the unnatural L-configuration are much less known, and their use in therapy of neoplastic and viral diseases is unknown.
  • nucleoside dimers In the synthesis of DNA-related oligomers, types of nucleoside dimers are synthesized as part of the overall process. These dimers usually include bases from naturally occurring DNA or RNA sequences. There is much known in the art about nucleoside monophosphate dimers. Many of these compounds have been synthesized and are available commercially. However, these dimers are made from nucleosides containing a sugar moiety in D-configuration.
  • Reese, C.B., Tetrahedron 34 (1978) 3143 describes the synthesis of fully-protected dinucleoside monophosphates by means of the phosphotriester approach.
  • the methods are applicable to synthesis of dimers, both by solution phase and solid phase methods. Both phosphitetriester and phosphotriester methods of coupling nucleosides are described.
  • the solid phase method is useful for synthesizing dimers.
  • dimers with L-deoxyribofuranosyl moieties in any position are new, as are dimers with L-ribofuranosyl moieties bonded to the 3'-position of the phosphate internucleotide bond.
  • Modified nucleoside analogues represent an important class of compounds in the available arsenal of antineoplastic and antiviral drugs.
  • antisense oligonucleotide analogues with modified bases and/or phosphodiester backbones have been actively pursued as antiviral and antitumor agents. While no clinically approved drug has yet emerged from this class of compounds, it remains a very active field of research.
  • antipodal L-sugar-based nucleosides also have found application as potent antiviral agents because they can inhibit viral enzymes without affecting mammalian enzymes, resulting in agents that have selective antiviral activity without concomitant mammalian cytotoxicity.
  • nucleosides Most naturally occurring nucleosides have the D-configuration in the sugar moiety. While the chemical properties of L-nucleosides are similar to those of their ⁇ -D-enantiomers, they exhibit very different biological profiles in mammalian cells and do not interfere with the transport of normal D-nucleosides. For example, ⁇ -L-uridine is not phosphorylated at the 5'-position by human prostate phosphotransferase, which readily phosphorylates the enantiomeric ⁇ -D-uridine. Moreover, L-nucleosides are not substrates for normal human cell kinases, but they may be phosphorylated by viral and cancer cell enzymes, allowing their use for the design of selective antiviral and anticancer drugs.
  • Oligonucleotides based on L-nucleosides have been studied previously. Octamers derived from ⁇ - and ⁇ -L-thymidine were found resistant to fungal nucleases and calf spleen phosphodiesterase, which readily degrades the corresponding ⁇ -D-oligonucleotide. Fujimory, et al., S. Fujimory, K. Shudo, Y. Hashimoto, J. Am. Chem. Soc, 112, 7436, have shown that enantiomeric poly- ⁇ -DNA recognizes complementary RNA but not complementary DNA. This principle has been used in the design of nuclease-resistant antisense oligonucleotides for potential therapeutic applications.
  • L-nucleoside-based compounds have potential as drugs against neoplastic, fungal, and viral diseases, as well as against parasitic infections. While L-sugar-derived nucleosides and their oligonucleotides have been widely evaluated for such activities, little is known regarding the biological activities of shorter oligomers such as dimers obtained by L-nucleoside substitution.
  • This invention comprises novel L-nucleoside-derived antitumor, antiviral, antibacterial, antifungal, and antiparasitic agents.
  • Novel L-nucleoside-derived dinucleoside monophosphates based on L- ⁇ -5-fluoro-2'-deoxyuridine showed a remarkably high potency activity profile in in vitro assays, with indications of unique mechanisms of action, including inhibition of telomerase. Therefore, the L-nucleosides can serve as building blocks for new drugs with the special advantage of low toxicity.
  • a further embodiment of the present invention is the administration of a therapeutically effective amount of the compounds of the present invention for the treatment of cancer, viral infections, parasitic infections, fungal infections, and bacterial infections.
  • Figure 1 is a schematic representation of examples of the dinucleotide dimers of the present invention.
  • Figures 2-14 are schematic representations of examples of the synthesis schemes followed in the present invention.
  • Figures 15A and 15B are schematic representations of examples of dinucleoside phosphate dimers containing alternate backbones.
  • Figures 16A-16D are schematic representations of dinucleoside phosphate dimers used in the examples.
  • the term "dimers" as used herein is defined by the structures shown in Figure 1. These compounds are L-nucleoside-derived dinucleoside monophosphates.
  • the B 1 and B 2 units will consist of either a ⁇ -D, a ⁇ -L or an ⁇ -L nucleoside and at least one of B ⁇ or B 2 will be ⁇ -L or ⁇ -L.
  • R and R 2 will be the pyrimidine bases cytosine, thymine, uracil, or 5-fluorouridine (5-FUdR) other 5-halo compounds, or the purine bases, adenosine, guanosine or inosine.
  • the dimers can be bound by various linkages.
  • Permissible linkages include 5'-3', 3'-5', 3'-3', 5'-5', 2'-3', 3'-2', 2' ⁇ 2', 2'-5', 5'-2', or any other stereochemically permissible linkage.
  • the sugar part of the nucleoside may be fully oxygenated, or may be in the deoxy or dideoxy form.
  • Specific antidisease compounds which are useful in the present invention include 3'-O-( ⁇ -L-5-fluoro-2'-deoxyuridinyl)- ⁇ -D-5-fluoro-2'-deoxyuridine,(L-102), 3'-O-( ⁇ -D-5-fluoro-2'-deoxyuridinyl)- ⁇ -L-5-fluoro-2'-deoxyuridine, (L-103), 3'-O-( ⁇ -D-5-fluoro-2'-deoxyuridinyl)- ⁇ -L-2'-deoxyuridine, (L-107), 3'-O-( ⁇ -L-5-fluoro-2'-deoxyuridinyl)- ⁇ -L-5-fluoro-2'-deoxyuridine, (L-108), 3'-O-( ⁇ -L-5-fluoro-2'-deoxyuridinyl)- ⁇ -L-5-fluoro-2'-deoxyuridine, (L-109), 3'-O-( ⁇ -D-5-fluoro-2
  • nucleotide binding agent or "IBA” means the backbone binding which links the nucleosides together.
  • IBA internucleotide binding agent
  • Figure 6 where methoxy phosphotriesters, methylphosphonates, phosphorodithioates, phosphorothioates, silyl ethers, sulphonates and ethylenedioxy ethers are shown.
  • the IBA's can be used to link the sugars 5'->3', 3' ⁇ 5', 3'-3', 5'-5', 2'-3', 3' ⁇ 2', 2'-2', 2'-5', 5' ⁇ 2', or any other stereochemically permissible linkages.
  • the sugars may be fully oxygenated, or may be in the deoxy or dideoxy form as permitted.
  • the IBA of the compounds is either phosphodiester or phosphorothioate.
  • the term "antidisease” as used herein refers to any of the activities of the compounds of the present invention to affect a disease state, including antitumor, antineoplastic, anticancer, antiparasitic and antiviral activity.
  • a compound or composition is said to be "pharmacologically acceptable” if its administration can be tolerated by a recipient mammal.
  • Such an agent is said to be administered in a "therapeutically effective amount” if the amount administered is physiologically significant.
  • An agent is physiologically significant if its presence results in technical change in the physiology of a recipient mammal. For example, in the treatment of cancer or neoplastic disease, a compound which inhibits the tumor growth or decreases the size of the tumor would be therapeutically effective; whereas in the treatment of a viral disease, an agent which slows the progression of the disease or completely treats the disease, would be considered therapeutically effective.
  • the antidisease compounds (active ingredients) of this invention can be formulated and administered to inhibit a variety of disease states (including tumors, neoplasty, cancer, bacterial, fungal, parasitic and viral diseases) by any means that produces contact of the active ingredient with the agent's site of action in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a combination of therapeutic active ingredients. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
  • the dosages given as examples herein are the dosages usually used in treating tumors, neoplasty and cancer. Lower doses may also be used. Dosages for antiparasitic and antiviral applications will, in general, be 10-50% of the dosages for anticancer applications.
  • the dosage administered will be a therapeutically effective amount of active ingredient and will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular active ingredient and its mode and route of administration; age, sex, health and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment and the effect desired.
  • a daily dosage (therapeutic effective amount) of active ingredient can be about 5 to 400 milligrams per kilogram of body weight. Ordinarily, 10 to 200, and preferably 10 to 50, milligrams per kilogram per day given in divided doses 2 to 4 times a day or in sustained release form is effective to obtain desired results.
  • Dosage forms (compositions) suitable for internal administration contain from about 1.0 to about 500 milligrams of active ingredient per unit.
  • the active ingredient will ordinarily be present in an amount of about 0.05-95% by weight based on the total weight of the composition.
  • the active ingredient can be administered orally in solid dosage forms such as capsules, tablets and powders, or in liquid dosage forms such as elixirs, syrups, emulsions and suspensions.
  • the active ingredient can also be formulated for administration parenterally by injection, rapid infusion, nasopharyngeal absorption or dermoabsorption.
  • the agent may be administered intramuscularly, intravenously, or as a suppository.
  • Gelatin capsules contain the active ingredient and powdered carriers such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • water a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration contain preferably a water soluble salt of the active ingredient, suitable stabilizing agents and, if necessary, buffer substances.
  • Antioxidizing agents such as sodium bisulfate, sodium sulfite or ascorbic acid, either alone or combined, are suitable
  • stabilizing agents are citric acid and its salts and sodium EDTA.
  • parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a standard reference text in this field.
  • control release preparations can include appropriate macromolecules, for example polymers, polyesters, polyaminoacids, polyvinyl, pyrolidone, ethylenevinylacetate, methyl cellulose, carboxymethyl cellulose or protamine sulfate.
  • concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release.
  • the agent can be incorporated into particles of polymeric materials such as polyesters, polyaminoacids, hydrogels, poly (lactic acid) or ethylenevinylacetate copolymers. In addition to being incorporated, these agents can also be used to trap the compound in microcapsules.
  • Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows.
  • Capsules are prepared by filling standard two-piece hard gelatin capsulates each with 100 milligram of powdered active ingredient, 175 milligrams of lactose, 24 milligrams of talc and 6 milligrams magnesium stearate.
  • Soft Gelatin Capsules A mixture of active ingredient in soybean oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are then washed and dried.
  • Tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient. 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of comstarch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or to delay absorption.
  • a parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume
  • aqueous suspension is prepared for oral administration so that each 5 millimeters contain 100 milligrams of finely divided active ingredient, 200 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution U.S. P. and 0.025 millimeters of vanillin.
  • the nucleosides and dimers may incorporate any stereochemcially permissible linkage and may include various oxygenated, deoxy, and dideoxy forms of the sugar rings.
  • the synthetic nucleosides and dimers described in the examples can include any of the substitutions discussed earlier.
  • the backbone and base modifying groups can be added. Various substitutions will enhance the affinity, the chemical stability and the cellular uptake properties of the specific dimers treatments.
  • CISiMe 3 (2.3 ml, 18.05 mmol) was added dropwise over 30 minutes to a stirring suspension of compound 17 (0.82 g, 3.61 mmol) in pyridine (50 ml) chilled in an ice bath.
  • BzCI (2.1 ml, 18.05 mmol) was then added dropwise and the reaction mixture was cooled at room temperature for two hours. The reaction mixture was again cooled in an ice bath and cold water (10 ml) was added dropwise. Fifteen minutes later, concentrated NH 4 OH (10 ml) was added to produce a solution of ammonia of a concentration of about 2M. Thirty minutes after the addition of the ammonia solution, a solvent was evaporated, dissolved in water and washed with ether. Evaporation of this aqueous solution provided the crude product (18) which was used in the next step without further purification.
  • the dimers were prepared from the monomeric materials by the general scheme shown in Scheme 2.
  • A. ⁇ -L. ⁇ -D 5 FUdR Dimer ⁇ '-O-dimethoxytrityl- ⁇ -L-S-fluoro ⁇ '-deoxyuridine (20a) ⁇ -L-5-fluoro-2'-deoxyuridine (8) (500 mg, 2.0 mmol) was dissolved in 10 ml of dry, distilled pyridine. To this solution was added 4,4'-dimethoxytrityl chloride (813 mg, 2.4 mmol) and 4-dimethylaminopyridine (DMAP) (50 mg, 0.4 mmol). The mixture was stirred under an argon atmosphere for 16 hours. After this time, the pyridine was stripped off in vacuo.
  • DMAP 4-dimethylaminopyridine
  • the 5'-O-dimethoxytrityl- ⁇ -L-5-fluoro-2'-deoxyuridine (20a, 548 mg, 1 mmol) was dissolved in anhydrous dichloromethane (20 ml).
  • N,N-diisopropylethylamine 700 ⁇ l, 4 mmol was added through a septum, followed by chloro-N,N-diisopropylmethoxyphosphine (290 ⁇ l, 1.5 mmol), under an argon atmosphere.
  • the reaction was stirred for 30 minutes.
  • the solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and brine.
  • the organic layer was washed with saturated NaHCO 3 solution and brine.
  • the dimer, 25a (504 mg), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (26 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 2.1 hours. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo.
  • the O-protected dimer, 26a (280 mg) was treated with 20 ml of saturated methanolic ammonia at room temperature until the reaction was completed at room temperature. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40° C in high vacuo to dryness to give the pure product (162 mg).
  • the dimer, 25b (526 mg), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (26 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue (578 mg) was dissolved in 10 ml of 80% acetic acid/water solution and was stirred for three hours.
  • the dimer, 25c (2.81 g, 3.2 mmol), was dissolved in a mixture of THF:pyridine:water (25:6:0.6). Iodine crystals (150 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo.
  • the O-protected dimer, 26c (465 mg, 0.78 mmol) was treated with 50 ml of saturated methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (370 mg, 87.7% yield).
  • the 5'-O-dimethoxytrityl- ⁇ -L-5-fluoro-2'-deoxyuridine (20d, 840 mg, 1.53 mmol) was dissolved in anhydrous dichloromethane (50 ml). N,N-diisopropylethylamine (1.1 ml, 6.13 mmol) was added through a septum, followed by chloro-N,N-diisopropylmethoxyphosphine (0.42 ml, 2.3 mmol), under an argon atmosphere. The reaction was stirred for 30 minutes. The solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and brine.
  • the dimer, 25d (960 mg, 1.07 mmol), was dissolved in a mixture containing
  • the O-protected dimer, 26d (300 mg, 0.49 mmol) was treated with 50 ml of saturated methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (240 mg, 85% yield).
  • the dimer in reduced form 25 (700 mg, 0.78 mmol), was dissolved in a mixture containing THF:pyridine:water (25:6:0.6). Iodine crystals (100 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 2.5 hours. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 25 ml of 80% acetic acid/water solution and was stirred until the reaction was completed.
  • the O-protected dimer, 26e (340 mg, 0.57 mmol) was treated with 100 ml of saturated methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2
  • the dimer, 25f (970 mg), was dissolved in 16 ml of THF and 4 ml of pyridine containing 0.4 ml of water. Iodine crystals (50 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 20 ml of 80% acetic acid/water solution and was stirred until the reaction was completed.
  • the O-protected dimer, 26f (200 mg) was treated with 20 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40° C in high vacuo to dryness to give the pure product (79 mg).
  • the dimer 25g (611 mg), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (30 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 20 ml of 80% acetic acid/water solution and was stirred until the reaction was completed.
  • the o-protected dimer, 26g (200 mg) was treated with 20 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (134 mg).
  • the O-protected dimer, 26h (400 mg) was treated with 100 ml of methnolic ammonia solution until the reaction is completed.
  • the solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40° C in high vacuo to dryness to give the pure product (175 mg).
  • N -benzoyl-2'-deoxy- ⁇ -L-cytidine (0.8 g, 2.42) was dissolved in 50 ml of dry, distilled pyridine. To this solution was added 4,4'-dimethoxytrityl chloride (3.0 g, 8.85 mmol) and 4-dimethylamino pyridine (DMAP) (60 mg, 0.48 mmol). The mixture was stirred under an argon atmosphere for 16 hours. After this time, the pyridine was stripped off in vacuo. The residue was dissolved in EtOAc (100 ml). The organic layer was washed with water, saturated NaHCO 3 , and brine.
  • DMAP 4-dimethylamino pyridine
  • the dimer, 25i (0.73 g), was dissolved in 20 ml of THF and 4 ml of pyridine containing 0.4 ml of water. Iodine crystals (100 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 25 ml
  • the O-protected dimer, 26i (108 mg) was treated with 100 ml of methnolic ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (56 mg).
  • the dimer, 25j (0.49 g), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (30 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was
  • the O-protected dimer, 26j (188 mg) was treated with 100 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (105 mg).
  • the dimer 25k (0.42 g), was dissolved in 10 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (45 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO 3 solution and brine. The organic layer was dried over Na 2 SO 4 , filtered and evaporated in vacuo. The residue was dissolved in 25 ml of 80% acetic acid/water solution and was stirred until the reaction was completed.
  • the O-protected dimer, 26k (125 mg) was treated with 100 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH 4 CO 3 buffer from 0.02-0.2 M). Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (40 mg).
  • telomerase is a DNA-processive enzyme that is not expressed in normal somatic cells but generally only in germ-line cells and fetal cells. In many types of cancer cells, enzyme activity is reactivated, and others, telomerase inhibitors can therefore serve as a valuable new class of antineoplastic agents. The results are shown in Table 2.
  • the preliminary results of the telomerase inhibition are also interesting.
  • the ⁇ -L, ⁇ -D dimer inhibited the enzyme by 84% compared to control.
  • dimers containing an L-sugar have extremely interesting biological profiles and represent a novel class of potent antineoplastic agents.
  • the activity profile of the L-dimers is different from that of the parent monomeric drug ⁇ -D-5FUdR.
  • Thymidylate synthase is one suspected site of action of the compounds.
  • the activity of selected compounds of the present invention measured on thymidylate synthase activity measured in vitro, is a reliable indicium of the behavior of these compounds in in vivo systems.
  • Mouse leukemia L1210 cells are harvested from the cell culture flasks and the cell concentration is determined. The cells are then resuspended in the desired amount of the medium to give a stock concentration 5x10 7 cells/mL. Series of the
  • 38 dilution of the stock solution of the compounds to be tested are prepared (concentrations are ranged from 10 8 M to 10 "3 M).
  • the solution of the compound to be tested in the desired concentration is pipetted into a microcentrifuge tube and incubated at 37 °C using a shaking water bath.
  • the reaction is started by addition of [5- 3 H]-2 '-deoxycytidine (10 ⁇ L, concentration of the stock solution - 10 "5 M) after a 30 or 60 min. preincubation with 80 ⁇ L of the cell suspension and allowed to proceed for 30 min. in a shaking water bath at 37°C.
  • the reaction is terminated by adding 100 ⁇ L of the 10% charcoal in 4% HC1 O 4 .
  • the tubes are vigorously stirred by vortexing and then centrifuged for 10 min. in a Beckman Microfuge.
  • the radioactivity of a 100 ⁇ L of supernatant fraction from each tube is counted in a Packard Tri-Carb (model 2450 or 3255) liquid scintillation spectrometer using a toluene based scintillation mixture.
  • the release of tritium is expressed as a percentage of the total amount of radioactivity added.
  • IC 50 values determined from dose response curves represent the concentration of inhibitors required for 50% inhibition of the release of tritium. Table 3 below shows the results of the analysis of tritium release and determination of the IC 50 .
  • B6D2F1 mice received i.p. inocula of P388 murine leukemia cells prepared by removing ascites fluid containing P388 cells from tumored B6D2F1 mice, centrifuging the cells, and then resuspending the leukemia cells in saline.
  • Mice received 1 x 10 6 P388 cells i.p. on day 0.
  • tumored mice were treated with the dimers or vehicle control.
  • the route of drug administration was i.p. and the schedule selected was daily x 5.
  • the maximum tolerated doses (MTD) was 200 mg/kg for each dimer and was determined in initial dose experiments in non-tumored mice. In the actual experiments, L-103 was given at 100 mg/kg and 50 mg/kg.
  • B6D2F1 mice received i.p. inocula of B16 murine melanoma brei prepared from B16 tumors growing s.c. in mice (day 0). On day 1 , tumored mice were treated with the dimers or vehicle control. The route of drug administration was i.p. and the schedule selected was daily x 5. The maximum tolerated doses (MTD) was 200 mg/kg for each dimer and was determined in initial dose experiments in non-tumored mice. In the actual experiments, L-103 was given at 100 mg/kg and 50 mg/kg.
  • T/C mean survival of control mice
  • mice that survive for 30 days are considered long term
  • T/C 125.
  • T/C 125-150, weak activity
  • T/C 150-200, modest activity
  • T/C 200-300, high activity
  • T/C > 300 with long term survivors; excellent, curative activity.
  • L-103 demonstrated modest activity against B16 melanoma implanted in mice (Table 6). L-103 (i.p.; daily x 5) gave T/C values of 139 and 134 respectively.
  • L-103 demonstrated modest activity against both the P388 and B16 experimental murine tumors at the two doses tested. L-103 was approximately as active as the positive control drug FUdR in the B16 test, and was somewhat less active than FUdR in the P388 test.
  • P. falciparum, FCQ27 was maintained in culture using the techniques described by Trager & Jensen (W. Traqer and J.B. Jensen, Science, 193 673-675 (1976)). Cultures containing 2% hematocrit suspensions of parasitized human type O+ erythrocytes in RPMI 1640 medium, supplemented with 25 mM HEPES-KOH, pH 7.2, 25 mM NaHCO3 and 10% human type O+ serum (v/v) are maintained in modular incubator chambers at 37° C in a gas mixture of 5% 02, 5% CO2 and 90% N2. The isolate of P. falciparum used in these experiments was FCQ27, routinely maintained in synchronized or asynchronous in vitro cultures at low hematocrit.
  • nucleoside analogues against P. falciparum in culture were tested in microtitre plates over the range of drug concentrations for 24 hours.
  • the procedures for monitoring parasite viability is well established (A.M. Gero, H.V. Scott, W.J. O'Sullivan and R.I. Christopherson, Mol. Biochem. Parasitol. 34, 87-89 (1989)) and is based on radiolabelled hypoxanthine or isoleucine incorporation.
  • the incorporation of [G-3H]hypoxanthine into the nucleic acids of P. falciparum was used to assess the viability of the parasite in vitro.
  • Microculture plates were prepared with each well containing 225 ⁇ l of a 2% hematocrit culture of asynchronous parasited erythrocytes (1% parasitized cells). Each plate, containing varying concentrations of the drug to be studied (up to 200 ⁇ M final concentration for initial screen), was incubated for 24 h at 37° C in a gas mixture of 5% O2, 5% CO2 and 90% N2, at which point [G-3H] hypoxanthine was added to each well and the incubation continued under identical conditions for a further 18-20 h. The control infected cells (i.e. without drug), routinely reached a parasitemia of 6-8% before harvesting.
  • the metabolism of the L-nucleoside conjugates was studied by HPLC analysis. The primary aim was to determine their ability to be catabolized by parasite purine salvage enzymes. Some effect on the purine metabolic pools was also observed.
  • trophozoite infected cells For each HPLC determination 200 ⁇ L of packed cells of 80-90% trophozoite infected cells were used. These were isolated from in vitro cultures by synchronization of the parasites in in vitro cultures using sterile D-sorbitol (L. Lambros and J.P. Vanderberg, Parasitol. 65, 418-420 (1979)) followed by separation of the trophozoites from non infected erythrocytes by Percoll gradients as described previously (A.M. Gero, H.V. Scott, W.J. O'Sullivan and R.I. Christopherson, Mol. Biochem. Parasitol. 34, 87-89 (1989)). Trophozoites were incubated at 37 °C for 2 hours with each compound to be tested.
  • Drug incubation was terminated by centrifugation through silicon oil using the method of Upston and Gero (J.M. Upston and A.M. Gero, Biochem. Biophys. Acta. 1236, 249-258 (1995)). This procedure separated intact trophozoites from extracellular non-transported drug solution.
  • nucleosides with potential chemotherapeutic activity were assessed by the analysis of cytoplasmic samples by reverse phase ion-pair high performance liquid chromatography (R.S. Toguzov, YN. Tikhonov, A.M. Pimenov, V. Prokudin, Journal of Chromatography, I. Biomedical Appl. 434, 447-453 (1988)). Nucleotides, nucleosides and bases were separated by this HPLC method.
  • Nucleosides have attracted researchers as potential therapeutic agents. Naturally occurring nucleosides are usually in the ⁇ -D configuration. Therefore most of nucleoside analogues designed for the treatment of cancer, viral and parasitic diseases have been synthesized in this stereochemical configuration. Recent discoveries in our laboratories at the University of Georgia, the University of Iowa and at Yale University, as well as at universities in France and Italy, have confirmed that most L-nucleosides exhibit low toxicity because normal cells do not utilize them for building RNA or DNA and don't metabolize them.
  • FUdR AS inhibitor of thymidylate synthase, and an L-nucleoside or its derivatives.
  • FUdR has a potential as an antimalarial agent (S.A. Queen, D.L. Vander Jagt & P. Reyer, Antimicrobial Agents & Chemotherapy. 34, 1393-1398 (1990).
  • FUdR's toxicity limits its use.
  • combining FUdR with an L-nucleoside unit would result in an entity that could selectively transport an active component to infected cells while having no effect on normal cells.
  • the conjugates tested were: a) dinucleoside phosphates, b) dinucleoside phosphorothioates, c) SATE derivatives of L-nucleosides, and d) L-nucleoside conjugates of nitrobenzylthionosine (NBMPR).
  • NBMPR nitrobenzylthionosine
  • the biological screen involved evaluation of the compounds against the protozoan P. falciparum in in vitro culture.
  • the range of drug concentrations was used independently by two assays.
  • microscopic counting of Giemsa stained thin slides was used as a control.
  • the results of the biological assays are presented in Table 1. Examples of experimental curves are attached as Appendix 2. The biological tests
  • A6 were done at several concentrations. The highest concentration was 200 ⁇ M, the compounds were considered active at concentrations less than 40 ⁇ M.
  • the dimer containing only the "non-natural” isomeric form of nucleoside (L-109) did not exhibit any activity.
  • ⁇ -D-isomer of FUdR is the active component of the dimer molecules.
  • the position of the active component in the dimer is important.
  • the ⁇ -D-FUdR needs to be connected to the 3'-OH end of the L-nucleoside through a phosphodiester linkage to its 5'-OH.
  • Compounds which are linked through 3'-OH of FUdR are much less active (see Table 7). This indicates that the substitution pattern of ⁇ -D-FUdR is critical for the activity of the dimers and most probably the mechanism involves thymidylate synthase inhibition. It is well known that TS inhibitors of FUdR have very rigid structural requirements and do not allow for any substitution at the 3' end.
  • L-138 ( ⁇ -L-da, ⁇ -D-FUdR) 5 L-138 ( ⁇ -L-dA, ⁇ -D-FUdR) 100
  • the different activity of the dimers is dependent on the structure of the second nucleoside.
  • Dimer may act as a new chemical entity without hydrolysis of the phosphate or pro-phosphate bond between the two monomeric units;
  • nucleoside analogs are dependent in kinase-mediated activation to generate the bioactive nucleotide and ultimately, the nucleoside triphosphate (C. Periqaud, G.
  • nucleoside monophosphates themselves, due to their polar nature, are not able to cross the cell membrane efficiently (K.C. Leibman, C.J. Heidelberg, J. Biol. Chem. 216, 823 (1995)). Hence the idea of temporarily masking or reducing the phosphate negative charges with neutral substituents, thereby forming more lipophilic derivatives which would be expected to revert back to the nucleoside mono-phosphate once inside the cell.
  • L-nucleoside dimers L-101 , L-103, L-103A, L-107, L-110, L-111 , L-112, L-114, L-117, L-120, L-122,
  • L-124, L-125, L-133 & L-138) from Lipitek's library were submitted for in vitro screen to the U.S. Army Antimalarial Test Program (for the structures of the compounds, see Figure 7).
  • the compounds have been tested for their activity against two P. falciparum strains: D6 (chloroquin non-resistant) and W2 (chloroquin resistant). Seven (7) of the tested compounds exhibited activities below 40 ⁇ M against both strains of P. falciparum.
  • the most active dimers were L-101 , L-110, L-112, L-117, L-133 & L-138.
  • Column 2 shows the retention times of the original compound remaining after incubation with whole parasite infected cell.
  • Column 3 shows the metabolic products i.e. new peaks due to conversion of the original compound or alteration in the natural purine or pyrimidine profile of the infected cell.
  • nucleosides monophosphate dimers containing ⁇ -D-FUdR unit in combination with any L-nucleosides (L-101 , L-103, L-111 , L-117, L-133, and L-138) as well as tested L-nucleoside monomer analogs (GC1 1007, GC1 1027 & GC1 1069) entered the infected cells. All these compounds were toxic against P. falciparum. The L-109, combination of two L-dimers,
  • Dimethoxytrityl- ⁇ -L-2'-deoxyuridine (1.5 g, 2.83 mmol) was dissolved in anhydrous dichloromethane (50 ml). N, N-diisopropylethylamine (2.0 ml, 11.3 mmol) was added uner argon followed by 2'-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.82 ml,
  • the dimer (2'-Acetoxy-N 6 -benzoyl-3'-deoxy- ⁇ -D-adenosinyl)- ⁇ -L-2'-deoxyuridinyl cyanoethyl phosphate ester (0.75 g) was treated with ammoniun hydroxide solution (100 ml) over night. The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH 4 HCO 3 buffer (0.05-0.2M). The pure fractions were collected and lyophillized to give pure 3'-O-(3'-deoxy- ⁇ -D-adenosinyl)- ⁇ -L-2'-deoxyuridine (L-150)(0.486 g) as
  • N 6 -benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy- ⁇ -L-adenosine (1.64 g, 2.5 mmol) was dissolved in anhydrous dichloromethane (50 ml).
  • N 6 -Benzoyl-5'-O-(dimethoxytrityl)- ⁇ -L-2'-deoxyadenosine-3'-N,N-diisoprop ylcyanoethyl phosphoramidite (2.5 mmol) in anhydrous acetonitrile (60 ml)
  • N 6 -Benzoyl-2'-O-acetoxy- ⁇ -D-3'-deoxyadenosine (0.94 g, 2.36 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon. 5
  • sublimed 1 H-tetrazole 0.5 g, 7.2 mmol
  • the dimer N 6 -Benzoyl-5'-O-(dimethoxytrityl)-3'-[O-(2'-O-acetyl)-N 6 -benzoyl- ⁇ -D-3-de oxy adenosinyl]-2'-deoxy- ⁇ -L-adenosine cyanoethyl phosphite was 5 dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.63 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate. The solvent was evaporated and the residue was dissolved in EtOAc and
  • the dimer (2'-Acetoxy-N 6 -benzoyl-3'-deoxy- ⁇ -D-adenosinyl)-N 6 -benzoyl- ⁇ -L-2'-deoxy adenosinyl cyanoethyl phosphate ester (0.97 g) was treated with ammonium hydroxide solution (100 ml) over night. The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH 4 HCO 3 buffer (0.05 - 0.2 M).
  • the dimer 5'-O-Dimethoxytrityl-3'-[O-(2'-O-acetyl)-N 6 -benzoyl- ⁇ -D-3'-deoxyadenosin yl]-2'-deoxy- ⁇ -L-uridine cyanoethyl phosphite ester was dissolved in THF
  • N 4 -Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy- ⁇ -L-cytidine (1.7 g, 2.68 mmol) was dissolved in anhydrous dichloromethane (50 ml), N, N-diisopropylethylamine (1.9 ml, 10.72 mmol) was added under argon followed by 2'-cyanoethyl-N, N-diisopropylchlorophosphoramidite (0.85 ml, 3.5 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated.
  • the dimer N 4 -Benzoyl-5'-O-dimethoxytrityl-3'-[O-(2'-O-acetyl)-N 6 -benzoyl- ⁇ -D-3'- ⁇ deo xyadenosinyl-2'-deoxy- ⁇ -L-cytidine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.55 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate.
  • N-diisopropylethylamine (2.0 ml, 11.6 mmol) was added under argon followed by 2'-cyanoethyl-N, N-diisopropylchlorophosphoramidite (0.85 ml, 3.5 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated. The residue was dissolved in 80% EtOAc/Et 3 N (75 ml) and washed with water, NaHCO 3 and brine.
  • the dimer N 4 -Benzoyl-5'-O-(dimethoxytrityl)-3'-[O-(2'-acetyl)-N 6 -Benzoyl- ⁇ -D-3'-deox y adenosinyl]-2'-deoxy- ⁇ -L-cytidine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.5 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate.
  • the dimer (2'-Acetoxy-N 6 -Benzoyl-3'-deoxy- ⁇ -D-adenosinyl)-N 4 -Benzoyl- ⁇ -L-2-deoxy citydinyl cyanoethyl phosphate ester (1.8 g) was treated with ammonium hydroxide solution (100 ml) over night, The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH 4 HCO 3 buffer (0.05 - 0.2M). The pure fractions were collected and lyophillized to give pure
  • N 6 -Benzoyl-3'-O-acetoxy- ⁇ -D-2'-deoxyadenosine (0.94 g, 2.36 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon.
  • sublimed 1 H-tetrazole 0.5 g, 7.2 mmol
  • the dimer N 6 -Benzoyl-5'-0-dimethoxytrityl-3'-[O-(2'-)-acetyl)-N 6 -benzoyl- ⁇ -D-3'-deoxy adenosinyl]-2'-deoxy- ⁇ -L-adenosine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.63 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate.
  • N 6 -Benzoyl-5'-O-(di-p-methoxy trityl )-2'-deoxy- ⁇ -L-adenosine (3.42 g, 74.5%) as pale yellow foam.
  • N 6 -Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy- ⁇ -L-adenosine(1.71 g, 2.61 mmol) was dissolved in anhydrous dichloromethane (50 ml).
  • N, N-diisopropylethylamine (1.8 ml, 10.34 mmol) was added under argon followed by 2'-cyanoethyl-N,N-diisopropylchlorophosphoramidite (1.0 ml, 4.47 mmol). o The reaction was stirred for 30 minutes, and the solvent was evaporated.
  • N 6 -Benzoyl-5'-O-dimethoxytrityl-3'-[O-(3'-O'acetyl)-N 6 -benzoyl- ⁇ -D-2'-deox y adenosinyl]-2'-deoxy- ⁇ -L-adenosine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.5 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes, and the excess iodine was removed by the addition of saturated sodium thiosulfate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to novel nucleosides and nucleoside dimers containing an L-sugar in at least one of the nucleosides, and their pharmaceutical compositions.

Description

NOVEL NUCLEOSIDE ANALOGS AND USES IN TREATING DISEASE
This Application is a continuation-in-part from U.S. Pat. Appl. Ser. No. 08/531,875, filed on September 21, 1995.
BACKGROUND OF THE INVENTION Field of Invention
This invention relates to novel nucleosides and dinucleoside dimers and derivatives of these compounds, including, L-deoxyribofuranosyl nucleoside phosphodiester dimers in which the sugar moiety of at least one of the nucleosides has an L-configuration. These compounds are highly effective in the treatment of various diseases. They may be used to treat parasitic infections such as the one caused by Plasmodium falciparum, the etiologic agent responsible for the most fatal form of malaria. They may also be used to treat bacterial, viral, and fungal infections, and may also be used to treat cancer.
Prior Art
Modified nucleoside analogs are an important class of antineoplastic and antiviral drugs. The present application discloses novel compounds for of this type for use in the treatment of P. falciparum infection and other parasitic infections. Plasmodium falciparum is the etiologic agent responsible for the most fatal form of malaria, a disease which afflicts between 200 and 300 million people per year (all forms), including over one million childhood deaths. Additionally, greater than 40% of the world's population lives in areas in which malaria is at epidemic levels. Due to the extraordinary morbidity and mortality associated with malaria and other parasitic infections, related research has intensified during the past decade in a desperate search for effective treatments. Safe and effective vaccines still do not exist. Instead, many victims must depend upon chemotherapy.
These modified nucleoside analogs may also be used to treat various other parasitic infections, bacterial infections, fungal infections, viral infections, and cancer.
These chemotherapeutic agents can be classified into two groups: those that act post-translationally, and those that act by interfering with nucleic acid synthesis. Most drugs are in the first group, which means that they exert their therapeutic effect by interfering with a cell's protein synthesis, and hence its metabolism (rather than its nucleic acid synthesis). Examples of drugs in this group include: the antifolate compounds (which inhibit dihyrdofolate reductase), and sulfonamide drugs (which inhibit dihydropteroate synthetase. Yet these drugs have serious drawbacks. For example, the protozoan responsible for malaria very quickly develops resistance to these drugs. The reason is that, since resistance occurs through adaptive mutations in successive generations of the parasite, a one or two point mutation is often sufficient to confer resistance. Bacterial, viral, and fungal infections are frequently also susceptible to these types of resistance mutations.
The second group of compounds includes the nucleic acid intercalators such as acridines, phenanthrenes and quinolines. These intercalators partially mimic the biochemical activity of nucleic acids, and therefore are incorporated into the protozoan's, or a cell's, nucleic acid (DNA and RNA), though once incorporated, do not allow further nucleic acid synthesis, hence their effectiveness. At the same time, these intercalators interfere with host nucleic acid synthesis as well, and thus give rise to toxic side effects. Because of the potential for toxic side effects, these drugs can quite often be given only in very small doses. Once again, a resistance pattern may develop. For example, a number of protozoans are known to develop "cross-resistance," which means that the parasites develop resistance to other classes of drugs even though they were exposed to a different class of drug.
Indeed, all of the currently known drugs or drug candidates utilizing the delivery of cytotoxic pyrimidine or purine biosynthesis inhibitors to invading cells are extremely toxic. Therefore, while drugs of this type-i.e., those that interfere with nucleic acid synthesis-are effective, they lack selectivity. It is this latter parameter that must be maximized in the development of a safe and effective drug. In other words, such a drug would target host tissues that are infected, or cancerous, yet leave the host tissue unchanged.
Recent advances in our understanding of the biochemistry of parasite cells serves as a valuable example regarding the design of effective therapies. One investigator (H. Ginsburg, Biochem. Pharmacol. 48, 1847-1856 (1994)) observed that normal and parasite-infected erythrocytes exhibit significant differences with respect to purine and pyrimidine metabolism in single enzymes, as well as in whole branches of related pathways. The parasite satisfies all of its purine requirements through scavenger pathways; meanwhile, the host cell lacks the enzymes necessary to exploit this pathway, and so therefore must meet its pyrimidine requirements largely through de novo synthesis. Put another way, the parasite is more efficient than normal or host cells since it can synthesize the nucleic acid building blocks.
Other investigators (G. Beaton, D. Pellinqer, W.S. Marshall & M. H. Caruthers, In: Oligonucleotides and Analogues: A Practical Approach, F. Eckstein Ed., IRL Press, Oxford, 109-136 (1991 )) have established that a malaria-infected erythrocyte is capable of effectively transporting the non-naturally occurring "L-nucleosides" (in contrast to the "D-nucleosides" which are the naturally occurring form) for use in nucleic acid synthesis. Yet, normal mammalian cells are nonpermeable to this class of compounds, which suggests that the L-nucleosides are non-toxic to normal mammalian or host cells. Thus, derivatives of these compounds may be used as highly selective drugs against parasite infection, or against any other type of cell or organism utilizing the L-nucleosides. The chemical modification of the L-nucleosides consists generally of modifying the nucleosides so that they are still recognized by the invading cell or organism's nucleic acid synthetic machinery, and therefore incorporated into a nucleic acid chain, but yet once this incorporation occurs, no further synthesis will take place.
Currently, there are no therapeutic compounds in use that are based on dimers of these nucleoside analogs. While dimers of the naturally occurring D-deoxyribofuranosyl nucleosides are well known, dimers in which one or both nucleosides are of the unnatural L-configuration are much less known, and their use in therapy of neoplastic and viral diseases is unknown.
In the synthesis of DNA-related oligomers, types of nucleoside dimers are synthesized as part of the overall process. These dimers usually include bases from naturally occurring DNA or RNA sequences. There is much known in the art about nucleoside monophosphate dimers. Many of these compounds have been synthesized and are available commercially. However, these dimers are made from nucleosides containing a sugar moiety in D-configuration.
Reese, C.B., Tetrahedron 34 (1978) 3143 describes the synthesis of fully-protected dinucleoside monophosphates by means of the phosphotriester approach.
Littauer, U.Z., and Soreg, H. (1982) in The Enzymes. Vol. XV, Academic Press, NY, p. 517 is a standard reference which describes the enzymatic synthesis of dinucleotides.
Heikkilό, J., Stridh, S., Oberg, B. and Chattopodhyaya, J., Acta Chem. Scand. B 39 (1985) 657-669, provides an example of the methodology used in the synthesis of a variety of ApG nucleoside phosphate dimers. Included are references and methods for synthesis of 3'-5' phosphates and 2'-5' phosphates by solution phase chemistry.
Gait, M., "Oligonucleotide Synthesis", IRL Press, Ltd., Oxford, England, 1984, is a general reference and a useful overview for oligonucleotide synthesis. The methods are applicable to synthesis of dimers, both by solution phase and solid phase methods. Both phosphitetriester and phosphotriester methods of coupling nucleosides are described. The solid phase method is useful for synthesizing dimers.
Gulyawa, V. and Holy, A, Coll. Czec. Chem. Commun. 44 613 (1979), describe the enzymatic synthesis of a series of dimers by reaction of 2', -3' cyclic phosphate donors with ribonucleoside acceptors. The reaction was catalyzed by non-specific RNases. The donors are phosphorylated in the 5'-position, yielding the following compounds: donor nucleoside-(3'→5') acceptor nucleoside. Dimers were made with acceptors, β-L-cytidine, β-L-adenosine, and 9(α-L-lyxofuranosyl) adenine. Also, a large number of dimers with D-nucleosides in the acceptor 5'- position were made.
Holy, A, Sorm, F., Collect. Czech. Chem. Commun., 34, 3383 (1969), describe an enzymatic synthesis of β-D-guanylyl-(3'→5')-β-L-adenosine and β-D-guanylyl-(3'-5')-β-L-cytidine.
Schirmeister, H. and Pfleiderer, W., Helv. Chim. Acta 77, 10 (1994), describe trimer synthesis and intermediate dimers, all from β-D-nucleosides. They used the phosphoramidite method which gave good yields.
Thus, dimers with L-deoxyribofuranosyl moieties in any position are new, as are dimers with L-ribofuranosyl moieties bonded to the 3'-position of the phosphate internucleotide bond.
Modified nucleoside analogues represent an important class of compounds in the available arsenal of antineoplastic and antiviral drugs. The anticancer agents 5-fluorodeoxyuridine (floxuridine), cytarabine and deoxycoformycin and the antiviral drugs 3'azidodeoxythymidine (AZT), dideoxycytidine (ddC), dideoxyinosine (ddl), acyclovir, 5-iododeoxyuridine (idoxuridine) fludarabine phosphate and vidarabine (adenine arabinoside/ara A) are representative of this class of monomeric nucleoside-derived compounds which are used therapeutically.
More recently, "antisense" oligonucleotide analogues with modified bases and/or phosphodiester backbones have been actively pursued as antiviral and antitumor agents. While no clinically approved drug has yet emerged from this class of compounds, it remains a very active field of research. Recently, antipodal L-sugar-based nucleosides also have found application as potent antiviral agents because they can inhibit viral enzymes without affecting mammalian enzymes, resulting in agents that have selective antiviral activity without concomitant mammalian cytotoxicity.
Most naturally occurring nucleosides have the D-configuration in the sugar moiety. While the chemical properties of L-nucleosides are similar to those of their β-D-enantiomers, they exhibit very different biological profiles in mammalian cells and do not interfere with the transport of normal D-nucleosides. For example, β-L-uridine is not phosphorylated at the 5'-position by human prostate phosphotransferase, which readily phosphorylates the enantiomeric β-D-uridine. Apparently, L-nucleosides are not substrates for normal human cell kinases, but they may be phosphorylated by viral and cancer cell enzymes, allowing their use for the design of selective antiviral and anticancer drugs.
Oligonucleotides based on L-nucleosides have been studied previously. Octamers derived from α- and β-L-thymidine were found resistant to fungal nucleases and calf spleen phosphodiesterase, which readily degrades the corresponding β-D-oligonucleotide. Fujimory, et al., S. Fujimory, K. Shudo, Y. Hashimoto, J. Am. Chem. Soc, 112, 7436, have shown that enantiomeric poly-α-DNA recognizes complementary RNA but not complementary DNA. This principle has been used in the design of nuclease-resistant antisense oligonucleotides for potential therapeutic applications.
Thus, L-nucleoside-based compounds have potential as drugs against neoplastic, fungal, and viral diseases, as well as against parasitic infections. While L-sugar-derived nucleosides and their oligonucleotides have been widely evaluated for such activities, little is known regarding the biological activities of shorter oligomers such as dimers obtained by L-nucleoside substitution.
This invention comprises novel L-nucleoside-derived antitumor, antiviral, antibacterial, antifungal, and antiparasitic agents. Novel L-nucleoside-derived dinucleoside monophosphates, based on L-α-5-fluoro-2'-deoxyuridine showed a remarkably high potency activity profile in in vitro assays, with indications of unique mechanisms of action, including inhibition of telomerase. Therefore, the L-nucleosides can serve as building blocks for new drugs with the special advantage of low toxicity.
SUMMARY OF THE INVENTION
A further embodiment of the present invention is the administration of a therapeutically effective amount of the compounds of the present invention for the treatment of cancer, viral infections, parasitic infections, fungal infections, and bacterial infections.
Other and further objects, features and advantages will be apparent from the following description of the present preferred embodiments of the invention given for the purposes of disclosure when taken in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic representation of examples of the dinucleotide dimers of the present invention. Figures 2-14 are schematic representations of examples of the synthesis schemes followed in the present invention.
Figures 15A and 15B are schematic representations of examples of dinucleoside phosphate dimers containing alternate backbones.
Figures 16A-16D are schematic representations of dinucleoside phosphate dimers used in the examples.
Certain features of the invention may be exaggerated in scale or shown in schematic form in accordance with the customary practices in the biochemical arts.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
It is readily apparent to one skilled in the art that various substitutions and modifications may be made to the invention disclosed in this Application without departing from the scope and spirit of the invention.
The term "dimers" as used herein is defined by the structures shown in Figure 1. These compounds are L-nucleoside-derived dinucleoside monophosphates. The B1 and B2 units will consist of either a β-D, a β-L or an α-L nucleoside and at least one of B^ or B2 will be β-L or α-L. R and R2 will be the pyrimidine bases cytosine, thymine, uracil, or 5-fluorouridine (5-FUdR) other 5-halo compounds, or the purine bases, adenosine, guanosine or inosine. As can be seen in Figure 1 , the dimers can be bound by various linkages. Permissible linkages include 5'-3', 3'-5', 3'-3', 5'-5', 2'-3', 3'-2', 2'→2', 2'-5', 5'-2', or any other stereochemically permissible linkage. The sugar part of the nucleoside may be fully oxygenated, or may be in the deoxy or dideoxy form.
Specific antidisease compounds which are useful in the present invention include 3'-O-(α-L-5-fluoro-2'-deoxyuridinyl)-β-D-5-fluoro-2'-deoxyuridine,(L-102), 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-α-L-5-fluoro-2'-deoxyuridine, (L-103), 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-α-L-2'-deoxyuridine, (L-107), 3'-O-(α-L-5-fluoro-2'-deoxyuridinyl)-α-L-5-fluoro-2'-deoxyuridine, (L-108), 3'-O-(β-L-5-fluoro-2'-deoxyuridinyl)-β-L-5-fluoro-2'-deoxyuridine, (L-109), 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-β-L-5-fluoro-2'-deoxyuridine, (L-110), 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-α-L-2'-deoxycytidine, (L-111 ), 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-2'-deoxy-β-L-cytidine (L-113), 3'-O-(2'-deoxy-β-L-cytidinyl)-β-D-5-fluoro-2'-deoxyuridine (L-114), 3'-O-(2'-deoxy-α-L-cytidinyl)-β-D-5-fluoro-2'-deoxyuridine (L-115), 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-β-L-2'-deoxyuridine (L-117), 3'-O-(β-L-5-fluoro-2'-deoxyuridinyl)-α-L-5-fluoro-2'-deoxyuridine (L-119), 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-α-L-5-fluoro-2'-deoxyuridine (3', 3') (L-122), 3'-O-(3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyuridine (L-150), 3'-O-(3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyadenosine (L-151 ), 3'-O-(3'-deoxy-β-D-adenosinyl)-α-L-2'-deoxyuridine (L-152), 3'-O-(3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxycytidine (L-153), 3'-O-(3'-deoxy-β-D-adenosinyl)-α-L-2'-deoxycytidine (L-154), 3'-O-(3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyadenosine (L-155), 3'-O-(2'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyadenosine (L-210), or a therapeutically acceptable salts of these foregoing compounds. In the currently preferred embodiment, 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-α-L-5-fluoro-2'-deoxyuridine, (L-103) is used.
The term "internucleotide binding agent" or "IBA" means the backbone binding which links the nucleosides together. Although one skilled in the art will readily recognize a variety of other backbones are available and useful in the present invention. For example, see Figure 6, where methoxy phosphotriesters, methylphosphonates, phosphorodithioates, phosphorothioates, silyl ethers, sulphonates and ethylenedioxy ethers are shown. Although shown schematically 3'— 5' the IBA's can be used to link the sugars 5'->3', 3'→5', 3'-3', 5'-5', 2'-3', 3'→2', 2'-2', 2'-5', 5'→2', or any other stereochemically permissible linkages. The sugars may be fully oxygenated, or may be in the deoxy or dideoxy form as permitted. In the preferred embodiment, the IBA of the compounds is either phosphodiester or phosphorothioate. The term "antidisease" as used herein refers to any of the activities of the compounds of the present invention to affect a disease state, including antitumor, antineoplastic, anticancer, antiparasitic and antiviral activity. A compound or composition is said to be "pharmacologically acceptable" if its administration can be tolerated by a recipient mammal. Such an agent is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant. An agent is physiologically significant if its presence results in technical change in the physiology of a recipient mammal. For example, in the treatment of cancer or neoplastic disease, a compound which inhibits the tumor growth or decreases the size of the tumor would be therapeutically effective; whereas in the treatment of a viral disease, an agent which slows the progression of the disease or completely treats the disease, would be considered therapeutically effective.
Dosage and Formulation
The antidisease compounds (active ingredients) of this invention can be formulated and administered to inhibit a variety of disease states (including tumors, neoplasty, cancer, bacterial, fungal, parasitic and viral diseases) by any means that produces contact of the active ingredient with the agent's site of action in the body of a mammal. They can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic active ingredients or in a combination of therapeutic active ingredients. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.
The dosages given as examples herein are the dosages usually used in treating tumors, neoplasty and cancer. Lower doses may also be used. Dosages for antiparasitic and antiviral applications will, in general, be 10-50% of the dosages for anticancer applications.
The dosage administered will be a therapeutically effective amount of active ingredient and will, of course, vary depending upon known factors such as the pharmacodynamic characteristics of the particular active ingredient and its mode and route of administration; age, sex, health and weight of the recipient; nature and extent of symptoms; kind of concurrent treatment, frequency of treatment and the effect desired. Usually a daily dosage (therapeutic effective amount) of active ingredient can be about 5 to 400 milligrams per kilogram of body weight. Ordinarily, 10 to 200, and preferably 10 to 50, milligrams per kilogram per day given in divided doses 2 to 4 times a day or in sustained release form is effective to obtain desired results.
Dosage forms (compositions) suitable for internal administration contain from about 1.0 to about 500 milligrams of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.05-95% by weight based on the total weight of the composition.
The active ingredient can be administered orally in solid dosage forms such as capsules, tablets and powders, or in liquid dosage forms such as elixirs, syrups, emulsions and suspensions. The active ingredient can also be formulated for administration parenterally by injection, rapid infusion, nasopharyngeal absorption or dermoabsorption. The agent may be administered intramuscularly, intravenously, or as a suppository.
Gelatin capsules contain the active ingredient and powdered carriers such as lactose, sucrose, mannitol, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions. Solutions for parenteral administration contain preferably a water soluble salt of the active ingredient, suitable stabilizing agents and, if necessary, buffer substances. Antioxidizing agents such as sodium bisulfate, sodium sulfite or ascorbic acid, either alone or combined, are suitable
10 stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben and chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a standard reference text in this field.
Additionally, standard pharmaceutical methods can be employed to control the duration of action. These are well known in the art and include control release preparations and can include appropriate macromolecules, for example polymers, polyesters, polyaminoacids, polyvinyl, pyrolidone, ethylenevinylacetate, methyl cellulose, carboxymethyl cellulose or protamine sulfate. The concentration of macromolecules as well as the methods of incorporation can be adjusted in order to control release. Additionally, the agent can be incorporated into particles of polymeric materials such as polyesters, polyaminoacids, hydrogels, poly (lactic acid) or ethylenevinylacetate copolymers. In addition to being incorporated, these agents can also be used to trap the compound in microcapsules.
Useful pharmaceutical dosage forms for administration of the compounds of this invention can be illustrated as follows.
Capsules: Capsules are prepared by filling standard two-piece hard gelatin capsulates each with 100 milligram of powdered active ingredient, 175 milligrams of lactose, 24 milligrams of talc and 6 milligrams magnesium stearate.
Soft Gelatin Capsules: A mixture of active ingredient in soybean oil is prepared and injected by means of a positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are then washed and dried.
Tablets: Tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient. 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of comstarch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or to delay absorption.
Injectable: A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume
11 propylene glycol and water. The solution is made isotonic with sodium chloride and sterilized.
Suspension: An aqueous suspension is prepared for oral administration so that each 5 millimeters contain 100 milligrams of finely divided active ingredient, 200 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution U.S. P. and 0.025 millimeters of vanillin.
Summary of Compounds Synthesized
The following examples are offered by way of illustration and are not intended to limit the invention in any manner. The nucleosides and dimers may incorporate any stereochemcially permissible linkage and may include various oxygenated, deoxy, and dideoxy forms of the sugar rings. The synthetic nucleosides and dimers described in the examples can include any of the substitutions discussed earlier. The backbone and base modifying groups can be added. Various substitutions will enhance the affinity, the chemical stability and the cellular uptake properties of the specific dimers treatments.
Example 1 Synthesis of 2'-deoxy-α-L-5-flourouridine
While β-D-5-fluoro-deoxyuridine is commercially available, the α-L-isomer 2'-deoxy-α-L-5-fluorouridine is not, and this component of the dimers was synthesized from L-arabinose. 1-(2', 3', 5'-tri-O-benzoyl-α-L-arabinofuranosvO-5-fluorouracil (3)
To a mixture of 5-fluorouracil (4.01 g, 30.87 mmol) and compound 2 (15.57 g, 30.87 mmol) in anhydrous MeCN were successively added HMDS (5.20 ml, 24.69 mmol), CISiMe3 (3.10 ml, 24.69 mmol), and SnCI4 (4.30 ml, 37.04 mmol). The resulting clear solution was refluxed for one hour. Then the solvent was evaporated and the residue was dissolved in EtOAc (750 ml), washed with H2O, and saturated NaHCO3 solution. The EtOAc layer was dried over sodium sulfate, filtered and evaporated to give the crude product. This crude product was purified on a silica gel column using 40-50% EtOAc/petroleum ether to give pure 3 (11.7 g, 66.0%
12 yield) as a white foam.
NMR: (CDCI3) δ = 4.65 (dd, 1 H), 4.78 (dd, 1 H), 4.97 (dd, 1 H, 5.75-5.88 (2 t, 2H),
6.27 (d, 1 H), 7.36-7.62 and 8.00-8.10 (m, 5H), 8.94 (d, 1 H).
1 -α-L-arabinofuranosyl-5-fluorouracil (4)
To a solution of compound 3 (11.7 g, 20.37 mmol) in MeOH (300 ml), NaOMe (4.2 ml of a methanolic 25% w/v solution) was added and the solution was stirred until the reaction was complete. The solvent was then evaporated and the residue was dissolved in H2O (200 ml), washed with ether and neutralized with Dowex 50 ion exchange resin. After filtration of the resin, the aqueous solution was evaporated to give compound 4 (4.92 g, 92% yield) as a white foam. NMR: (DMSO-d6) δ = 3.48 (m, 2H), 3.93-4.00 (2 t, 2H), 4.16 (q, 1 H), 5.69 (dd, 1 H), 8.03 (d, 1 H).
1 -re'.S'-O-d , 1.3.3-tetraisopropyldisiloxane-l ,3-divπ-α-L-arabinofuranosyll-5-fluorou racil (5)
To a stirred suspension of 4 (6.43 g, 24.52 mmol) in pyridine (200 ml) was added 1 ,3-dichloro-1 ,1 ,3,3-tetraisopropyldisiloxane (10.3 ml, 29.43 mmol). This was stirred at room temperature until the reaction was complete (5 hours). The solvent was evaporated to a residue which was dissolved in EtOAC and washed successively with H2O, 5% HCI, H2O, saturated NaHCO3, and brine. After drying the EtOAc portion over Na2SO4, the solution was filtered and evaporated to give the crude product 5 which was used in the next step without further purification. l-^'-O-phenoxythiocarbonyl-S'.δ'-O-d ,1 ,3,3-tetraisopropyldisiloxane-1 ,3-diyl)-α-L- arabinofuraosyl]-5-fluorouracil (6)
To a solution of 5 (24.52 mmol) in anhydrous MeCN (300 ml) were added 4-dimethylaminopyridine (DMAP) (5.80 g, 47.58 mmol), and phenylchlorothionoformate (3.85 ml, 26.98 mmol). The solution was stirred at room temperature for 24 hours. Then, the solvent was evaporated to a residue which was dissolved in EtOAc and washed successively with H2O, 5% HCI, H2O, saturated NaHCO3, and brine. After drying the EtOAc portion over Na2SO4, the solution was filtered and evaporated to an oil. The oil was purified on a silica gel column using 30% EtOAc/petroleum ether to produce pure 6 (8.9 g, 56.7% yield) as a yellow
13 foam.
NMR: (CDCy δ = 4.02 (m, 2H), 4.32 (m, 1 H), 4.76 (dd, 1 H), 6.10 (dd, 1 H), 6.18 (dd,
1 H), 7.07-7.48 (m, 6H), 8.41 (br s, 1 H).
3'.5'-O-d .1.3,3-tetraisopropyldisiloxane-1 ■3-diyl)-α-L-2'-deoxy-5-fluorouridine (7)
To a solution of 6 (8.92 g, 13.91 mmol), in dry toluene (300 ml) was added AIBN (0.46 g, 2.78 mmol) followed by Bu3SnH (20.0 ml, 69.35 mmol). The solution was deoxygenated with argon and heated at 75 °C for four hours. The solvent was then evaporated and the residue was purified on a silica gel column using 30% EtOAc/petroleum ether to give pure 7 (5.44 g, 80% yield) as a white foam. NMR: (CDCI3) δ = 2.16 (m, 1 H), 2.84 (m, 1 H), 3.8 Cm, 1 H), 4.07 (m, 1 H), 4.60 (m, 1 H), 6.19 (ddd, 1 H), 7.92 (m, 1 H). 2'-deoxy-a-L-5-fluorouridine (8)
A solution of compound 7 (5.44 g, 11.13 mmol) and NH4F (4.12 g, 111.3 mmol) in MeOH was stirred in an oil bath at 60°C for 3 hours. Silica gel (3 g) was added and the mixture was evaporated to a dry powder. This powder was added to a silica column and eluted with 10-15% MeOH/CHCI3 to produce pure 8 (2.4 g, 87.6% yield) as a white foam.
NMR: (DMSO-d6) δ = 1.90 (m,1 H), 2.55 (m, 1 H), 3.33 (m,2H), 4.19 (m, 2H), 4.86 (br s, 1 H), 5.43 (br s, 1 H), 6.10 (dd, 1 H), 8.15 (d, 1 H), 11.78 (br s, 1 H).
Example 2 Synthesis of 2'-deoxy-α-L-uridine
1-(2', 3'. δ'-tri-O-benzoyl-α-L-arabinofuranosvO uracil (9)
To a mixture of uracil (1.17g, 10.49 mmol) and compound 2 (5 g) in anhydrous MeCN (100 ml) were successively added HMDS (1.77 ml, 8.39 mmol), CISiMe3 (1.06 ml, 8.39 mmol), and SnCI4 (1.47 ml, 12.58 mmol). The resulting clear solution was refluxed for one hour. Then the solvent was evaporated and the residue was dissolved in EtOAc (200 ml), washed with H2O, and saturated NaHCO3 solution. The EtOAc layer was dried over sodium sulfate, filtered and evaporated to give the crude product, which was purified on a silica gel column using 40-50% EtOAc/petroleum ether to give pure 9 (3.66 g, 62.7% yield) as a white foam.
14 NMR: (CDCI3) δ = 4.70 (m, 1 H), 5.77 (5, 1 H), 5.80 (dd, 1 H), 5.94 (t, 1 H), 6.20 (d, I H), 7.40-8.10 (m, 16H), 8.58 (br s, 1 H). 1 -α-L-arabinofuranosyl-uracil (10)
To a solution of compound 8 (17.83 g, 32.03 mmol) in MeOH (400 ml), NaOMe (5.0 ml of a methanolic 25% w/v solution) was added and the solution was stirred until the reaction was complete. The solvent was then evaporated and the residue was dissolved in H2O (250 ml), washed with ether and neutralized with Dowex 50 ion exchange resin. After filtration of the resin, the aqueous solution was evaporated to give compound 10 (7.4 g, 94.6% yield) as a white foam. This was used in the next step without further purification. l-rS'.δ'-o-d .l .S.S-tetraisopropyldisiloxane-I .S-divπ-α-L-arabinofuranosyll-uracil (11)
To a stirred suspension of 10 (7.4 g, 30.3 mmol) in pyridine was added 1.3-dichloro-1 ,1 ,3,3-tetraisopropyldisiloxane (12.74 ml, 36.36 mmol). This was stirred at room temperature until the reaction was complete (5 hours). The solvent was evaporated to a residue which was dissolved in EtOAC (500 ml) and washed successively with H2O, 5% HCI, H2O, saturated NaHCO3, and brine. After drying the EtOAc portion over Na2SO4, the solution was filtered and evaporated to give the crude product 11 which was used in the next step without further purification. 1-r2'-o-phenoxythiocarbonyl-3',5'-o-d .1.3.3-tetraisopropyldisiloxane-1 ,3-divO-α-L-ar abinofuranosyll-uracil (12)
To a solution of 11 (30.3 mmol) in anhydrous MeCN were added 4-dimethylaminopyridine (DMAP) (7.2 g, 58.78 mmol), and phenylchlorothionoformate (4.7 ml, 33.33 mmol). The solution was stirred at room temperature for 24 hours. Then, the solvent was evaporated to a residue which was dissolved in EtOAc (750 ml) and washed successively with H2O, 5% HCI, H2O, saturated NaHCO3, and brine. After drying the EtOAc portion over Na2SO4, the solution was filtered and evaporated to an oil. The oil was purified on a silica gel column using 30% EtOAc/petroleum ether to produce pure 12 (13.14 g, 74.5% yield) as a white foam.
NMR: (CDCI3)δ = 4.04 (m, 2H), 4.38 (m, 1 H), 4.73 (dd, 1 H), 5.79 (dd, 1 H), 5.93 (d, 1 H), 6.31 (dd, 1 H), 7.08-7.33 (m, 6H), 9.2 (br s, 1 H).
15 3'.5'-o-d .1 ,3,3-tetraisopropyldisiloxane-1.S-divD-α-L^'-deoxyuridine (13)
To a mixture of 12 (13.14 g, 21.09 mmol), in dry toluene (300 ml) was added AIBN (0.69 g, 4.2 mmol) followed by Bu3SnH (28.4 ml, 105.4 mmol). The solution was deoxygenated with argon and heated at 75°C for four hours. The solvent was then evaporated and the residue was purified on a silica gel column using 30% EtOAc/petroleum ether to give pure 13 (9.29 g, 88.4% yield) as a white foam. NMR: (CDCI3) δ = 2.15 (2 t, 1 H), 2.81 (m, 1 H), 3.82 (dd,1 H), 4.05 (m, 2H), 4.56 (q, 1 H), 5.75 (dd, 1 H), 6.16 (t, 1 H), 7.69 (d, 1 H), 9.38 (br s, 1 H). 2,-deoxy-α-L-uridine (14)
A mixture of compound 13 (9.2 g, 18.63 mmol) and NH4F (6.9 g, 186.3 mmol) in MeOH (200 ml) was stirred in an oil bath at 60°C for 3 hours. Silica gel (5 g.) was added and the mixture was evaporated to a dry powder. This powder was added to a silica column and eluted with 10-15% MeOH/CHCI3 to produce pure 14 (3.70 g, 83% yield) as a white foam.
NMR: (DMSO-d6) δ = 1.87 (m, 1 H), 2.56 (m, 1 H), 3.41 (m, 2H), 4.15 (m, 1 H), 4.22 (m, 1 H), 4.44 (t, 1 H), 4.92 (t, 1 H), 5.38 (d, 1 H), 5.62 (d, 1 H), 6.09 (dd, 1 H).
Example 3 Synthesis of 2,-deoxy-α-L-cytidine
S'.δ'-di-O-benzoyl^'-deoxy-α-L-uridine S)
A solution of BzCN (0.61 g, 4.67 mmol) in MeCN (10 ml) was added dropwise to a suspension of compound 14 (0.43 g, 1.87 mmol) in MeCN (10 ml) followed by Et3N (0.1 ml). The reaction was stirred at room temperature for three hours after which time the solvent was evaporated to dryness. The crude material was purified on a silica gel column using 50% EtOAc/petroleum ether to give pure 15 (0.57 g, 70% yield) as yellow foam.
NMR: (CDCI3) δ = 2.55 (d, 1 H), 2.96 (dt, 1 H), 4.56 (m, 2H), 4.86 (t, 1 H), 5.61 (d, 1 H), 5.73 (dd, 1 H), 6.31 (dd, 1 H), 7.40-7.63 (m, 7H), 7.87-8.06 (m, 4H), 8.82 (br s, 1 H). S'.δ'-di-O-benzoyl^'-deoxy^-thio-α-L-uridine S)
A boiling solution of compound 15 (0.54 g, 1.25 mmol) in anhydrous dioxane
16 was treated with P2S5 (0.61 g, 2.75 mmol) and the mixture was refluxed under a nitrogen atmosphere for one hour. Remaining solids were filtered from the hot solution and washed on the filter with additional dioxane. The filtrate was evaporated to dryness and the crude product was purified on a silica gel column using 30% EtOAc/petroleum ether to give pure 16 (0.42 g, 74% yield) as a yellow oil.
NMR: (CDCI3) δ = 2.59 (d, 1 H), 2.93 (dt, 1 H), 4.58 (m, 2H), 4.89 (t, 1 H), 5.63 (d, 1 H), 6.26 (dd, 1 H), 6.41 (dd, 1 H), 7.40-8.10 (m, 11 H), 9.54 (br s, 1 H). 2,-deoxy-α-L-cvtidine (17)
Compound 16 (0.42 g, 9.28 mmol) was treated with NH3/MeOH (50 ml) in a steel bomb at 100°C for 10 hours. After cooling, the solvent was evaporated to dryness, the residue was dissolved in water (50 ml) and washed with ether (3 x 50 ml). The water layer was treated with charcoal, filtered through Celite and evaporated to dryness by coevaporation with EtOH. The semi-solid obtained was crystallized from EtOH/ether to give compound 17 (0.18 g, 85.7% yield). NMR: (DMSO-d6) δ = 1.86 (Cd,H), 2.50 (m, 1 H), 3.40 (m, 1 H), 4.12 (m, 1 H), 4.15 (m, 1 H), 4.86 (t, 1 H), 5.21 (d, 1 H), 5.69 (d, 1 H), 6.03 (dd, 1 H), 7.02 (br d, 1 H), 7.74 (d, 1 H). N4-benzoyl-2'-deoxy-α-L-cytidine (18)
CISiMe3 (2.3 ml, 18.05 mmol) was added dropwise over 30 minutes to a stirring suspension of compound 17 (0.82 g, 3.61 mmol) in pyridine (50 ml) chilled in an ice bath. BzCI (2.1 ml, 18.05 mmol) was then added dropwise and the reaction mixture was cooled at room temperature for two hours. The reaction mixture was again cooled in an ice bath and cold water (10 ml) was added dropwise. Fifteen minutes later, concentrated NH4OH (10 ml) was added to produce a solution of ammonia of a concentration of about 2M. Thirty minutes after the addition of the ammonia solution, a solvent was evaporated, dissolved in water and washed with ether. Evaporation of this aqueous solution provided the crude product (18) which was used in the next step without further purification.
17 Example 4 Synthesis of Dimers
The dimers were prepared from the monomeric materials by the general scheme shown in Scheme 2.
A. α-L. β-D 5 FUdR Dimer δ'-O-dimethoxytrityl-α-L-S-fluoro^'-deoxyuridine (20a) α-L-5-fluoro-2'-deoxyuridine (8) (500 mg, 2.0 mmol) was dissolved in 10 ml of dry, distilled pyridine. To this solution was added 4,4'-dimethoxytrityl chloride (813 mg, 2.4 mmol) and 4-dimethylaminopyridine (DMAP) (50 mg, 0.4 mmol). The mixture was stirred under an argon atmosphere for 16 hours. After this time, the pyridine was stripped off in vacuo. The residue was dissolved in EtOAc (50 ml). The organic layer was washed with saturated NaHCO3, water and with brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo to a residue which was purified on a silica gel column using 10% MeOH/CHCI3. Pure fractions were pooled and evaporated to give the pure product as an off-white foam (679 mg, 86% yield). Rf = 0.48 in 10% MeOH/CHCI3.
NMR: (DMSO-d6) δ = 2.3 (dd, 1 H), 2.72-2.81 (m, 1 H), 3.15-3.26 (m, 2H), 3.75 (s, 6H), 4.45 (m, 2H), 6.23 (dd, 1 H), 6.92 (d, 1 H), 7.2-7.3 (m, 13 H), 7.94 (d, 1 H). S'-O-dimethoxytrityl-α-L-S-fluoro^'-deoxyuridine-S'-N.N-diisopropylmethoxy phosphoramidite (21a)
The 5'-O-dimethoxytrityl-α-L-5-fluoro-2'-deoxyuridine (20a, 548 mg, 1 mmol) was dissolved in anhydrous dichloromethane (20 ml). N,N-diisopropylethylamine (700 μl, 4 mmol) was added through a septum, followed by chloro-N,N-diisopropylmethoxyphosphine (290 μl, 1.5 mmol), under an argon atmosphere. The reaction was stirred for 30 minutes. The solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and brine. The organic layer was washed with saturated NaHCO3 solution and brine. The organic residue was evaporated to dryness and the residue was purified on a silica gel column using a mixture of dichloromethane, EtOAc and triethylamine (45:45: 10;Rf = 0.69). The product (390 mg) was isolated as a yellow foam and it
18 was used in the next step without further purification. 3'-Acetoxy-β-D-5-fluoro-2'-deoxyuridine (24a) β-D-5-fluoro-2'-deoxyuridine (500 mg, 2.2 mmol) was dissolved in 10 ml of dry, distilled pyridine. To this solution was added 4,4'-dimethoxytrityl chloride (813 mg, 2.4 mmole) and 4-dimethylaminopyridine (DMAP) (50 mg, 0.4 mmole). The mixture was stirred at room temperature for 16 hours. The pyridine was stripped off in vacuo. The residue was dissolved in dichloromethane (50 ml). The organic layer was washed with 0.3 N HCI, brine, saturated NaHCO3, and again with brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo to a residue which was purified on a silica gel column, eluting with 10% MeOH/CHCI3. Pure fractions were pooled and evaporated to give the pure product as an off-white foam (685 mg, 86% yield). This material was dissolved in pyridine (12 ml) and treated with acetic anhydride (2.5 ml) for 3 hours at room temperature. The solvent was evaporated, and the residue was dissolved in ethyl acetate. The ethyl acetate was washed as described above, dried over sodium sulfate and evaporated. The residue was then treated with 80% acetic acid (10 ml) for 2.5 hours at room temperature. The solvent was evaporated in vacuo and the residue was chromatographed on silica gel, eluting with 10% MeOH/CHCI3 to give pure 24a as a white foam, yield 422 mg.
NMR: (DMSO-d6) δ = 1.95 (s, 3H), 2.08-2.24 (m, 2H), 3.65-3.9 (m, 2H), 4.45 (m, 1 H), 4.72 (m, 1 H), 6.24 (dd, 1 H), 8.24 (d, 1 H). δ'-O-dimethoxytrityl-S^rO-O'-O-acetvD-β-D-S-fluoro^'-deoxyuridinyll-α-L-δ-fluoro^ '-deoxyuridine (25a)
The 3'-O-acetyl-β-D-5-fluoro-2'-deoxyuridine (188 mg, 0.65 mmol) was dissolved in dry acetonitrile (5 ml). Sublimed 1 H-tetrazole (80 mg) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21a (380 mg, 0.54 mmol), dissolved in 5 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam
19 (468 mg). This foam was used in the next step without further purification. (3,-acetoxy-β-D-5-fluoro-2,-deoxyuridinyl)-α-L-5-fluoro-2, -deoxyuridine methyl phosphonate ester (26a)
The dimer, 25a (504 mg), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (26 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 2.1 hours. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue (530 mg) was dissolved in 10 ml of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 20% MeOH/CHCI3. Fractions containing one spot by TLC (10% MeOH/CHCI3 Rf=0.35) were pooled and evaporated to give the pure product (316 mg).
NMR: (CD3OD) δ = 2.08 (s, 3H), 2.25-2.45 (m, 3H), 2.65-2.72 (m, 1 H), 3.60 (m, 2H), 3.80 (2d, 3H), 4.18 (m, 1 H), 4.28 (m, 1H), 4.35 (dd, 1 H), 4.62 (dd, 1 H), 5.05 (dd, 1 H), 5.23 (m, 1 H), 6.13 (m, 1 H), 6.18 (m, 1 H), 7.85 (m, 2H). P31 NMR: (CD3OD) δ = 0.77 (s), 1.16 (s). 3'-O-(β-D-5-fluoro-2,-deoxyuridinyl)-α-L-5-fluoro-2 -deoxyuridine (27a)
The O-protected dimer, 26a (280 mg) was treated with 20 ml of saturated methanolic ammonia at room temperature until the reaction was completed at room temperature. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40° C in high vacuo to dryness to give the pure product (162 mg).
NMR: (D20) δ = 2.2-2.4 (m, 3H), 2.65-2.71 (m, 1 H), 3.65 (m, 2H), 4.01 (m, 1 H), 4.11 (t, 1 H), 4.45 (m, 1 H), 4.65 (t, 1 H), 6.14 (d, 1 H), 6.24 (td, 1 H), 8.06 (d, 1 H), 8.02 (d, 1 H). 31P NMR: (D2O) δ = 0.04 (s).
20 B. β-D. α-L 5FUdR Dimer
S'-O-dimethoxytrityl-S'-rO-O'-O-acetvD-α-L-S-fluoro^'-deoxyuridinyll-β-D-δ-fluoro^ '-deoxyuridine (25b)
The 3'-O-acetyl-α-L-5-fluoro-2'-deoxyuridine, 24b (188 mg, 0.65 mmol) was dissolved in dry acetonitrile (5 ml). Sublimed 1 H-tetrazole (80 mg) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21b (380 mg, 0.54 mmol), dissolved in 5 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam (484 mg). This foam was used in the next step without further purification. (3f-acetoxy-α-L-5-fluoro-2'-deoxyuridinyl)- -D-5-fluoro-2, -deoxyuridine methyl phosphate ester (26b)
The dimer, 25b (526 mg), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (26 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue (578 mg) was dissolved in 10 ml of 80% acetic acid/water solution and was stirred for three hours. The solvent was evaporated and the residue was purified on a silica gel column, using 10-15% MeOH/CHCI3. Fractions containing one spot by TLC (10% MeOH/CHCI3 Rf - 0.35) were pooled and evaporated to give the pure product (342 mg).
NMR: (DMSO-d6) δ = 1.98 (s, 3H), 2.2-2.4 (m, 3H), 2.62-2.71 (m, 1 H), 3.5-3.8 (m, 4H), 4.02 (m, 1 H), 4.42 (m, 2H), 6.10 (dd, 1 H), 6.26 (dt, 1 H), 8.00 (d, 1 H), 8.04 (d, 1 H). 3,-O-(α-L-5-fluoro-2,-deoxyuridinyl)-β-D-5-fluoro-2,-deoxyuridine (27b)
The O-protected dimer, 26b (170 mg) was treated with 20 ml of saturated
21 methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (89 mg).
NMR: (D2O) δ = 2.2-2.4 (m, 3H), 2.65-2.71 (m, 1 H), 3.54-3.85 (m, 5H), 4.05 (t, 1 H), 4.42 (m, 2H), 6.06 (dd, 1 H), 6.23 (dt, 1 H), 8.00 (d, 1 H), 8.04 (d, 1 H).
C. α-L uridine. β-D 5 FUdR dimer
5'-O-(di-p-methoxytrityl)-2'-deoxy-α-L-uridine (20c) α-L-2 '-deoxvuridine (1.5 g, 6.57 mmol) was dissolved in 25 ml of dry, distilled pyridine. To this solution was added 4,4'-dimethoxytrityl chloride (2.9 g, 7.89 mmol) and 4-dimethylamino pyridine (DMAP) (160 mg, 1.31 mmol). The mixture was stirred under an argon atmosphere for 16 hours. After this time, the pyridine was stripped off in vacuo. The residue was dissolved in EtOAc (150 ml). The organic layer was washed with saturated NaHCO3, water and again with brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo to a residue which was purified on a silica gel column using 5% MeOH/CHCI3. Pure fractions were pooled and evaporated to give the pure product as an off-white foam (2.84 g, 81 % yield).
NMR: (CDCI3-d6) δ = 2.29 (d, 1 H), 2.70 (m, 2H), 3.17 (m, 2H), 3.78 (s, 6H), 4.44 (m, 2H), 5.63 (d, 1 H), 6.19 (d, 1 H), 6.83 (d, 4H), 7.28 (m, 9 H), 7.68 (d, 1 H), 9.30 (br s, 1 H).
5'-O-(dimethoxytrityl)-α-L-2'-deoxyuridine-3'-N,N-diisopropylmethoxy phosphoramidite (21c)
The 5'-O-dimethoxytrityl-α-L-2'-deoxyuridine (2.35 g, 4.43 mmol) was dissolved in anhydrous dichloromethane (50 ml). N,N-diisopropylethylamine (3.1 ml, 17.72 mmol) was added through a septum, followed by chloro-N,N-diisopropylmethoxyphosphine (1.3 ml, 6.64 mmol), under an argon atmosphere. The reaction was stirred for 30 minutes. The solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and
22 brine. The organic layer was washed with saturated NaHCO3 solution and brine. The organic residue was evaporated to dryness and the residue was purified on a silica gel column using a mixture of dichloromethane, EtOAc and triethylamine (40:50:10; Rf = 0.69). The product was isolated quantitatively as a yellow foam and it was used in the next step without further purification.
5'-O-dimethoxytrityl-3' O-(3'-O-acetyl)-β-D-5-fluoro-2'-deoxyuridinvn-2'-deoxy-α-L- uridine (25c)
The 3'-O-acetyl-β-D-5-fluoro-2'-deoxyuridine (0.95 g, 3.29 mmol) was dissolved in dry acetonitrile (125 ml). Sublimed 1 H-tetrazole (350 mg, 4.91 ) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21c (4.91 mmol), dissolved in 5 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam. This compound was further purified on a silica gel column using 5% MeOH/CHCI3 to give the pure product (2.81 g, 97% yield). S'-acetoxy-β-D-δ'-fluoro^'-deoxyuridinvD-α-L^'-deoxyuridine methyl phosphate ester (26c)
The dimer, 25c (2.81 g, 3.2 mmol), was dissolved in a mixture of THF:pyridine:water (25:6:0.6). Iodine crystals (150 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue (1.48 g) was dissolved in 25 ml of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 10% MeOH/CHCI3. Fractions containing one spot by TLC (10% MeOH/CHCI3 Rf = 0.4) were pooled and evaporated to give the pure product (0.465 g, 25% yield).
23 NMR: (CD3OD) δ = 2.09 (d, 3H), 2.40 (m, 3H), 2.80 (m, 1 H), 3.78 (dd, 3H), 4.30 (m,
3H), 4.63 (m, 1 H), 5.05 (m, 1 H), 5.23 (m, 1 H), 5.70 (d, 1 H), 6.13 (m, 1 H), 6.20 (m,
1 H), 7.73 (d, 1 H), 7.82 (d, 1 H).
P31 NMR: (CD3OD) δ = 0.56 (s), 0.84 (s).
3 '-O-(β-D-5-fluoro-2'-deoxyuridinyl)-α-L-2 '-deoxyuridine (27c)
The O-protected dimer, 26c (465 mg, 0.78 mmol) was treated with 50 ml of saturated methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (370 mg, 87.7% yield).
NMR: (CD3OD) δ = 2.23 (m, 2H), 2.29 (d, 1 H), 2.73(m, 1 H), 4.0 (d, 2H), 4.42 (m, 1 H), 4.56 (m, 1 H), 4.81 (m, 1 H), 5.69 (d, 1 H), 6.24 (m, 2H), 7.85 (d, 1 H), 8.02 (d, 1 H). P31 NMR: (CD3OD) δ = 1.25 (s).
D. β-L. β-L 5 FUdR dimer δ'-O-dimethoxytrityl-β-L-S-fluoro^'-deoxyuridine (20d) β-L-5-fluoro-2'-deoxyuridine (19d, 1.42 g, 5.77 mmol) was dissolved in 25 ml of dry, distilled pyridine. To this solution was added 4,4'-dimethoxytrityl chloride (2.34 g, 6.92 mmol) and 4-dimethylamino pyridine (DMAP) (140 mg, 1.15 mmol). The mixture was stirred under an argon atmosphere for 16 hours. After this time, the pyridine was stripped off in vacuo. The residue was dissolved in EtOAc (100 ml). The organic layer was washed with saturated NaHCO3, and with brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo to a residue which was purified on a silica gel column using 5% MeOH/CHCI3. Pure fractions were pooled and evaporated to give the pure product as an off-white foam (2.88 g, 88.7% yield).
NMR: (CDCI3) δ = 2.25 (m, 1 H), 2.50 (m, 1 H), 3.50 (m, 2H), 3.80 (s, 6H), 4.08 (m, 1 H), 4.58 (m, 1 H), 6.30 (t, 1 H), 6.84 (d, 4H), 7.28 (m, 9 H), 7.82 (d, 1 H), 8.58 (br s, 1 H).
24 5'-O-dimethoxytrityl-β-L-5-fluoro-2'-deoxyuridine-3'-N.N-diisopropylmethoxy phosphoramidite (21 d)
The 5'-O-dimethoxytrityl-β-L-5-fluoro-2'-deoxyuridine (20d, 840 mg, 1.53 mmol) was dissolved in anhydrous dichloromethane (50 ml). N,N-diisopropylethylamine (1.1 ml, 6.13 mmol) was added through a septum, followed by chloro-N,N-diisopropylmethoxyphosphine (0.42 ml, 2.3 mmol), under an argon atmosphere. The reaction was stirred for 30 minutes. The solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and brine. The organic layer was washed with saturated NaHCO3 solution and brine. The organic residue was evaporated to dryness and the residue was purified on a silica gel column using a mixture of dichloromethane, EtOAc and triethylamine (45:45:10; Rf = 0.69). The product (700 mg, 65%) was isolated as a yellow foam and it was used in the next step without further purification. 5'-O-dimethoxytrityl-3'-rθ-(3'-O-acetyl)-β-L-5-fluoro-2'-deoxyuridinyl1-β-L-5-fluoro-2 '-deoxyuridine (25d)
The 3'-acetyl-β-L-5-deoxyuridine, 24d (330 mg, 1.15 mmol) was dissolved in dry acetonitrile (50 ml). Sublimed 1 H-tetrazole (120 mg, 1.77 mmol) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21 d (950 mg, 1.36 mmol), dissolved in 5 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam. This foam was purified on a silica gel column using 5% MeOH/CHCI3 to give the pure product (960 mg, 93% yield).
NMR: (CDCI3) δ = 2.10 (d, 3H), 2.28 (m, 2H), 2.49 (m, 2H), 3.42 (m, 3H), 3.51 (dd, 3H), 3.76 (s, 6H), 4.07 (m, 1 H), 4.55 (m, 1 H), 4.87 (m, 1 H), 5.23 (m, 1 H), 6.30 (m, 2H), 6.84 (d, 4H), 7.30 (m, 9H), 7.82 (m, 2H).
(3'-acetoxy-β-L-5-fluoro-2'-deoxyuridinyl)-β-L-5-fluoro-2'-deoxyuridine methyl phosphate ester (26d)
The dimer, 25d (960 mg, 1.07 mmol), was dissolved in a mixture containing
25 THF:pyridine:water (12:3:0.3). Iodine crystals (50 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue (530 mg) was dissolved in 20 ml of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 10% MeOH/CHCI3. Fractions containing one spot by TLC (10% MeOH/CHCI3 Rf = 0.35) were pooled and evaporated to give the pure product (310 mg, 46% yield).
NMR: (CD3OD) δ = 2.08 (s, 3H), 2.35-2.54 (m, 4H), 3.79 (m, 2H), 3.83 (dd, 3H), 4.18 (m, 2H), 5.08 (m, 1 H), 5.29 (m, 1 H), 6.24 (m, 1 H), 7.86 (dd, 1 H), 8.19 (dd, 1 H). P31 NMR: (CD3OD) δ = 0.82 (s), 1.03 (s). 3'-O-(β-L-5-fluoro-2'-deoxyuridinyl)-β-L-5-fluoro-2'-deoxyuridine (27d)
The O-protected dimer, 26d (300 mg, 0.49 mmol) was treated with 50 ml of saturated methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (240 mg, 85% yield).
NMR: (CD3OD) δ = 2.25 (m, 3H), 2.50 (m, 1 H), 3.79 (d, 2H), 4.03 (m, 1 H), 4.08 (m, 2H), 4.18 (m, 1 H), 4.44 (m, 1 H), 4.90 (m, 1 H), 6.25 (t, 1 H), 8.01 (d, 1 H), 8.24 (d, 1 H). P31 NMR: (CD3OD) δ = 0.18 (s).
E. β-L. β-D 5 FUdR dimer
5'-O-dimethoxytrityl-3'-fO-(3'-O-acetyl)-β-D-5-fluoro-2'-deoxyuridinvn-β-L-5-fluoro-2 '-deoxyuridine (25e)
The 3'-O-acetyl-β-D-5-fluoro-2'-deoxyuridine (250 mg, 0.97 mmol) was dissolved in dry acetonitrile (50 ml). Sublimed 1 H-tetrazole (100 mg, 1.46 mmol)
26 was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21e (1.02 g, 1.46 mmol), dissolved in 5 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam. This foam was purified on a silica gel column using 5% MeOH/CHCI3 to give the pure product quantitatively.
O'-acetoxy-β-D-S-fluoro^'-deoxyuridinvD-β-L-S-fluoro^ '-deoxyuridine methyl phosphonate ester (26e)
The dimer in reduced form, 25 (700 mg, 0.78 mmol), was dissolved in a mixture containing THF:pyridine:water (25:6:0.6). Iodine crystals (100 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 2.5 hours. Excess iodine was discharged by the addition of a few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was dissolved in EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was dissolved in 25 ml of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 10% MeOH/CHCI3. Fractions containing one spot by TLC (10% MeOH/CHCI3 Rf = 0.35) were pooled and evaporated to give the pure product (340 mg, 71.4% yield).
NMR: (DMSO-d6) δ = 2.06 (s, 3H), 2.37 (m, 4H), 3.45 (m, 2H), 3.65 (d, 3H), 4.20 (m, 3H), 4.95 (m, 1 H), 5.30 (m, 1 H), 5.96 (m, 1 H), 6.15 (t, 2H), 7.99 (d, 1 H), 8.16 (d, 1 H), 11.90(br s, 2H).
P31 NMR: (DMSO-d6) δ = 1.93 (s), 2.01 (s). 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-β-L-5-fluoro-2'-deoxyuridine (27e)
The O-protected dimer, 26e (340 mg, 0.57 mmol) was treated with 100 ml of saturated methanolic ammonia at room temperature until the reaction was completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2
27 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (200 mg, 66.9% yield).
NMR: (CD3OD) δ = 2.20 (m, 3H), 2.53 (m, 1 H), 3.79 (d, 2H), 4.05 (m, 3H), 4.16 (m,
1 H), 4.45 (m, 1 H), 6.27 (t, 2H), 8.01 (d, 1 H), 8.04 (d, 1 H), 8.26 (d, 1 H).
5'-O-(dimethoxytrityl)-α-L-5-fluoro-2'-deoxyuridine-3'-N,N-diisopropylcvanoethyl phosphoramidite (21f)
The 5'-o-dimethoxytrityl-α-L-5-fluoro-2'-deoxyuridine (1.48 g, 2.71 mmol) was dissolved in anhydrous dichloromethane (50 ml). N,N-diisopropylethylamine (1.9 ml, 10.84 mmol) was added through a septum, followed by 2'-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.78 ml, 3.52 mmol), under an argon atmosphere. The reaction was stirred for 30 minutes. The solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and brine. The organic layer was washed with saturated NaHCO3 solution and brine. The organic residue was evaporated to dryness and the residue was purified on a silica gel column using a mixture of dichloromethane, EtOAc and triethylamine (45:45: 10:Rf=0.7). The product was isolated quantitatively as a yellow foam and it was used in the next step without further purification. 5'-O-dimethoxytrityl-3'-rθ-(5'-O-dimethoxytrityl)-β-D-5-fluoro-2'-deoxyuridinyll-α-L-5 -fluoro-2 '-deoxyuridine (25f)
The 5'-O-dimethoxytrityl-β-D-5-fluoro-2'-deoxyuridine (0.44 g, 0.81 mmol) was dissolved in dry acetonitrile (20 ml). Sublimed 1 H-tetrazole (90 mg) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21f (0.51 mg, 0.67 mmol), dissolved in 10 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam (970 mg). This foam was used in the next step without further purification.
28 (β-D-5-fluoro-2'-deoxyuridinyl)-α-L-5-fluoro-2'-deoxyuridine cvanoethyl phosphonate ester (26f)
The dimer, 25f (970 mg), was dissolved in 16 ml of THF and 4 ml of pyridine containing 0.4 ml of water. Iodine crystals (50 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was dissolved in 20 ml of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 10-15% MeOH/CHCL3. Fractions containing one spot by TLC (10% MeOH/CHCL3 Rf=0.35) were pooled and evaporated to give the pure product (330 mg). 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-α-L-5-fluoro-2'-deoxyuridine (27f)
The O-protected dimer, 26f (200 mg) was treated with 20 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40° C in high vacuo to dryness to give the pure product (79 mg).
NMR: (CD3OD) δ = 2.45 (m, 3H), 2.69 (m, 1 H), 3.67 (m, 2H), 3.76 (m, 2H), 4.13 (t, 1 H), 4.65 (m, 2H), 6.19 (m, 2H), 7.98 (td, 2H). P31 NMR: (D2O) δ = -1.0(s)
5'-O-dimethoxytrityl-3'-fO-(3'-O-acetyl)-β-L-5-fluoro-2'-deoxyuridinyll-α-L-5-fluoro-2 '-deoxyuridine (25g)
The 3'-O-acetyl-β-D-5-fluoro-2'-deoxyuridine (0.19 g, 0.67 mmol) was dissolved in dry acetonitrile (20 ml). Sublimed 1 H-tetrazole (70 mg) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21f (0.51 mg, 0.67 mmol), dissolved in 10 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a
29 residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam (611 mg). This foam was used in the next step without further purification.
(3'-acetoxy-β-L-5-fluoro-2'-deoxyuridinyl)-α-L-5-fluoro-2'-deoxyuridine cvanoethyl phosphonate ester (26g)
The dimer, 25g (611 mg), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (30 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was dissolved in 20 ml of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 10-15% MeOH/CHCL3. Fractions containing one spot by TLC (10% MeOH/CHCL3 Rf=0.35) were pooled and evaporated to give the pure product (200 mg).
3'-O-(β-L-5-fluoro-2'-deoxyuridinyl)-α-L-5-fluoro-2'-deoxyuridine (27q) fα-L β-L 5FUdR Dimerl
The o-protected dimer, 26g (200 mg) was treated with 20 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (134 mg).
NMR: (D2O) δ = 2.30 (m, 3H), 2.71 (m, 1 H), 3.65 (m, 2H), 4.03 (m, 2H), 4.08 (t, 1 H), 4.47 (m, 1 H), 4.68 (m, 2H), 6.13 (d, 1 H), 6.24 (td, 1 H), 7.89 (d, 1 H), 7.95 (d, 1 H). P31NMR: (D2O) δ = 0.32(s)
5'-O-(dimethoxytrityl)-β-L-2'-deoxyuridine-3'-N,N-diisopropylmethoxy phosphoramidite (21 h)
The 5'-O-dimethoxytrityl-α-L-2'-deoxyuridine (1.0 g, 1.88 mmol) was
30 dissolved in anhydrous dichloromethane (50 ml). N,N-diisopropylethylamine (1.31 ml, 7.55 mmol) was added through a septum, followed by chloro-N,N-diisopropylmethoxyphosphine (0.55 ml, 2.83 mmol), under an argon atmosphere. The reaction was stirred for 30 minutes. The solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and brine. The organic layer was washed with saturated NaHCO3 solution and brine. The organic residue was evaporated to dryness and the residue was purified on a silica gel column using a mixture of dichloromethane, EtOAc and triethylamine (50:40:10; Rf=0.8). The product was isolated quantitatively as a yellow foam and it was used in the next step without further purification.
5'-O-dimethoxytrityl-3'-fO-(3'-O-acetyl)-β-D-5-fluoro-2'-deoxyuridinvn-β-L-2'-deoxyu ridine (25h)
The 3'-O-acetyl-β-D-5-fluoro-2'-deoxyuridine (0.54 g, 1.88 mmol) was dissolved in dry acetonitrile (50 ml). Sublimed 1 H-tetrazole (200 mg) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21 h (1.88 mmol), dissolved in 15 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam (1.08 g). This foam was used in the next step without further purification.
(3'-acetoxy-β-D-5-fluoro-2'-deoxyuridinyl)-β-L-2'-deoxyuridine methyl phosphonate ester (26h)
The dimer, 25h (1.08 g), was dissolved in 15 ml of THF and 3 ml of pyridine containing 0.3 ml of water. Iodine crystals (100 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was dissolved in 25 ml
31 of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 10-15% MeOH/CHCL3. Fractions containing one spot by TLC (10% MeOH/CHCL3 Rf=0.4) were pooled and evaporated to give the pure product (400 mg). 3 '-O-(β-D-5-fluoro-2'-deoxyuridinyl)-β-L-2 '-deoxyuridine (27h)
The O-protected dimer, 26h (400 mg) was treated with 100 ml of methnolic ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40° C in high vacuo to dryness to give the pure product (175 mg).
NMR: (D2O) δ = 2.40 (m, 3H), 2.61 (m, 1 H), 3.80 (m,2H), 4.10 (m, 2H), 4.18 (m,2H), 4.55 (m, 1 H), 4.80 (m, 1 H), 5.85 (d, 1 H), 6.30 (q, 2H), 7.85 (d, 1 H), 8.06 (d, 1 H). P31NMR: (D2O) δ = 0.20(s) 5'-O-dimethoxytri-tyl-N -benzoyl-2'-deoxy-β-L-cvtidine (20i)
N -benzoyl-2'-deoxy-β-L-cytidine (0.8 g, 2.42) was dissolved in 50 ml of dry, distilled pyridine. To this solution was added 4,4'-dimethoxytrityl chloride (3.0 g, 8.85 mmol) and 4-dimethylamino pyridine (DMAP) (60 mg, 0.48 mmol). The mixture was stirred under an argon atmosphere for 16 hours. After this time, the pyridine was stripped off in vacuo. The residue was dissolved in EtOAc (100 ml). The organic layer was washed with water, saturated NaHCO3, and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo to a residue which was purified on a silica gel column using 10% MeOH/CHCI3. Pure fractions were pooled and evaporated to give the pure product as an off-white foam (1.49 g, (97% yield). Rf=0.48 in 10% MeOH/CHCI3.
NMR: (CDCI3-d6) δ = 2.3 (m, 1 H), 2.75 (m, 2H), 3.42 (ddd, 2H), 3.80 (s, 6H), 4.15 (q, 2H), 4.52 (m, 1 H), 6.30 (t, 1 H), 6.82 (dd, 4H), 7.2-7.6 (m, Ar), 7.85 (d, 2H), 8.32 (d, 1 H), 8.76 (br s, 1 H).
5'-O-(dimethoxytrityl)-N4-benzoyl-2'-deoxy-β-L-cvtidine-3'-N.N-diisopropylmethyl phosphoramidite (21 i)
The 5'-O-dimethoxytrityl-N4-benzoyl-2'-deoxy-β-L-cytidine (0.6 g, 0.95 mmol)
32 was dissolved in anhydrous dichloromethane (50 ml). N,N-diisopropylethylamine (0.66 ml, 3.79 mmol) was added through a septum, followed by chloro-N,N-diisopropylmethoxyphosphine (0.28 ml, 1.42 mmol), under an argon atmosphere. The reaction was stirred for 30 minutes. The solvent was evaporated and the residue was partitioned between an 80% EtOAc/triethylamine mixture and brine. The organic layer was washed with saturated NaHCO3 solution and brine. The organic residue was evaporated to dryness and the residue was purified on a silica gel column using a mixture of dichloromethane, EtOAc and triethylamine (60:30: 10;Rf=0.8). The product was isolated quantitatively as a yellow foam and it was used in the next step without further purification.
5'-O-dimethoxytrityl-3'-fO-(3'-O-acetyl)-β-D-5-fluoro-2'-deoxyuridinvn-N4-benzoyl-2' -deoxy-β-L-cvtidine (25i)
The 3'-O-acetyl-β-D-5-fluoro-2'-deoxyuridine (0.23 g, 0.78 mmol) was dissolved in dry acetonitrile (30 ml). Sublimed 1 H-tetrazole (110 mg) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21 i (0.94 mmol), dissolved in 15 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam (0.73 g). This foam was used in the next step without further purification.
(3'-acetoxy-β-D-5-fluoro-2'-deoxyuridinyl)-N4-benzoyl-2'-deoxy-β-L-cvtidine methyl phosphonate ester (26i)
The dimer, 25i (0.73 g), was dissolved in 20 ml of THF and 4 ml of pyridine containing 0.4 ml of water. Iodine crystals (100 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was dissolved in 25 ml
33 of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 10-15% MeOH/CHCI3. Fractions containing one spot by TLC (10% MeOH/CHCI3 Rf=0.4) were pooled and evaporated to give the pure product (108 mg). 3'-O-(β-D-5-fluoro-2'-deoxyuridinyl)-2'-deoxy-β-L-cvtidine (27i)
The O-protected dimer, 26i (108 mg) was treated with 100 ml of methnolic ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (56 mg). NMR: (D2O) δ = 2.30 (m, 3H), 2.55 (m, 1 H), 3.80 (m, 2H), 4.05 (m, 2H), 4.18 (m, 2H), 4.52 (m, 1 H), 4.78 (m, 1 H), 6.02 (d, 1 H), 6.25 (m, 2H), 7.80 (d, 1 H), 8.04 (d, 1 H).
P31NMR: (D2O) δ = 0.05(s)
5'-O-dimethoxytrityl-3'-rθ-(3'-O-acetyl)-N -benzoyl-2'-deoxy-β-L-cvtidinyl)-β-D-5-flu oro-2 'deoxyuridine (25i)
The 3'-O-acetyl-β-D-5-fluoro-2'-deoxyuridine (0.25 g, 0.67 mmol) was dissolved in dry acetonitrile (30 ml). Sublimed 1 H-tetrazole (94 mg) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21j (0.51 g, 0.67 mmol), dissolved in 15 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam (0.49 g). This foam was used in the next step without further purification. (3'-acetoxy-N4-benzoyl-2'-deoxy-β-L-cvtidinyl)-β-D-5-fluoro-2'-deoxyuridinyl cvanoethyl phosphonate ester (26i)
The dimer, 25j (0.49 g), was dissolved in 8 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (30 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was
34 discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was dissolved in 20 ml of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 10-15% MeOH/CHCI3. Fractions containing one spot by TLC (10% MeOH/CHCI3 Rf=0.4) were pooled and evaporated to give the pure product (188 mg). 3'-O-(2'-deoxy-β-L-cvtidinyl)-β-D-5-fluoro-2'-deoxyuridine (27i)
The O-protected dimer, 26j (188 mg) was treated with 100 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M. Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (105 mg). NMR: (D2O) δ = 2.30 (m, 3H), 2.50 (m, 1 H), 3.80 (m, 2H), 4.05 (m, 2H), 4.10 (m, 2H), 4.20 (m, 1 H), 4.52 (m, 1 H), 4.75 (m, 1 H), 6.05 (d, 1 H), 6.29 (q, 2H), 7.89 (d, 1 H), 9.03 (d, 1 H). P31NMR: (D2O) δ = 0.05(s)
5'-O-dimethoxytrityl-3'-rθ-(3'-O-acetyl)-N4-benzoyl-2'-deoxy-α-L-cvtidinyl)-β-D-5-flu oro-2 '-deoxyuridine (25k)
The 3'-O-acetyl-β-D-5-fluoro-2'-deoxyuridine (0.19 g, 0.51 mmol) was dissolved in dry acetonitrile (30 ml). Sublimed 1 H-tetrazole (80 mg) was added and the mixture was stirred under an argon atmosphere for 15 minutes. The solution of 21 k (0.45 g, 0.61 mmol), dissolved in 15 ml of dry acetonitrile was added via syringe to the reaction solution over 5 minutes. The mixture was allowed to stir at room temperature for three hours. The acetonitrile was evaporated in vacuo to a residue. This residue was triturated with a 70% EtOAc/ether mixture. The undissolved tetrazole was filtered off and the filtrate was evaporated to give a dry yellow foam (0.42 g). This foam was used in the next step without further purification.
35 (3'-acetoxy-N4-benzoyl-2'-deoxy-α-L-cvtidinyl)-β-D-5-fluoro-2'-deoxyuridinyl cvanoethyl phosphonate ester (26k)
The dimer, 25k (0.42 g), was dissolved in 10 ml of THF and 2 ml of pyridine containing 0.2 ml of water. Iodine crystals (45 mg) were added and the contents of the loosely stoppered flask were allowed to stir for 1 hour. Excess iodine was discharged by the addition of few drops of saturated sodium thiosulfate. The reaction mixture was then evaporated to dryness. The crude product was EtOAc washed with saturated NaHCO3 solution and brine. The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was dissolved in 25 ml of 80% acetic acid/water solution and was stirred until the reaction was completed. The solvent was evaporated and the residue was purified on a silica gel column, using 10-15% MeOH/CHCI3. Fractions containing one spot by TLC (10% MeOH/CHCi3 Rf=0.4) were pooled and evaporated to give the pure product (125 mg). 3'-O-(2'-deoxy-α-L-cvtidinyl)-β-D-5-fiuoro-2'-deoxyuridine (27k)
The O-protected dimer, 26k (125 mg) was treated with 100 ml of concentrated ammonia solution until the reaction is completed. The solvent was stripped off in vacuo and the residue was purified on DEAE cellulose ion exchange column using gradient of NH4CO3 buffer from 0.02-0.2 M). Pure fractions were evaporated at 40°C in high vacuo to dryness to give the pure product (40 mg). NMR: (D2O) δ = 2.15 (m, 1 H), 2.35 (m, 1 H), 2.60 (m, 1 H), 2.71 (m, 1 H), 3.81 (m, 2H), 3.97 (m, 2H), 4.22 (m, 1 H), 4.52 (m, 2H), 6.02 (d, 1 H), 6.15 (dd, 1 H), 6.28 (t, 1 H), 7.87 (d, 1 H), 8.03 (d, 1 H). P31NMR: (D2O) δ = 0.12(s)
Example 5
Dimers Testing In Vitro in B16 Melanoma and
P388 Leukemia and in Inhibition Assays Against
293 Processive Telomerase
The biological effects of the dimers were compared with those of the monomeric 5-FUdR on P388 leukemia and B16 melanoma cell lines and in inhibition
36 assays against 293 processive telomerase. Telomerase is a DNA-processive enzyme that is not expressed in normal somatic cells but generally only in germ-line cells and fetal cells. In many types of cancer cells, enzyme activity is reactivated, and others, telomerase inhibitors can therefore serve as a valuable new class of antineoplastic agents. The results are shown in Table 2.
Table 1 - Inhibition of Tumor Cell Growth and Telomerase Activity by 5-FUdR Dinucleoside Monophosphates
[Compound Growth Inhibition Telomerase ICsn (nM) Inhibition
P388 B16 (Mean+SEM) % at 1 mN β-D FUDR 2.8 28 0 α-L, β-D Dimer 0.41 2.45 84+11
Figure imgf000039_0001
α-L FUDR NT 389,500 NT
NT = Not Tested
The results indicate that the prototype dimers inhibit the growth of murine-cultured leukemic L1210 and melanoma B16 cells with great potency (some IC50 values of less than 1 nM.) The IC50 values are several times more potent than FUdR. These results are unexpected and thus these compounds are truly unique.
The preliminary results of the telomerase inhibition are also intriguing. The α-L, β-D dimer inhibited the enzyme by 84% compared to control.
These data indicate that dimers containing an L-sugar have extremely interesting biological profiles and represent a novel class of potent antineoplastic agents. The activity profile of the L-dimers is different from that of the parent monomeric drug β-D-5FUdR.
The biological effects of the dimers were compared with those of the monomeric 5-FUdR on P388 leukemia and B16 melanoma cell lines. The results
37 are shown in Table 2.
Table 2 - In Vitro Testing Data
IC50 (nM)
CODE # COMPOUND P388 B16
L-102 β-D-FUdR, α-L-FUdR 0.71 3.0
L-103 α-L-FUdR, β-D-FUdR 0.57 2.45
L-107 α-L-dU, β-D-FUdR 7.0 219
L-108 α-L-FUdR, α-L-FUdR 22,200 52,200
L-109 β-L-FUDR, β-L-FUdR 5860 45,900
L-110 β-L-FUdR, β-D-FUdR 2.0 6.3
L-111 α-L-dC, β-D-FUdR OJ 5.0
— β-D-FUdR 2.8 28]
Figure imgf000040_0001
These data indicate that the dinucleoside monophosphate compounds containing β-D-5FUdR in conjunction with α-L or β-L-nucleosides show superior in vitro activities against murine P388 leukemia and B16 melanoma cell lines, as is evidenced by lower IC50 values. This indicates that such nucleoside dimers may indeed be acting by mechanisms different from those of 5-FUdR or are metabolized and/or transported differently from 5-FUdR.
Example 6
Determination of Thymidylate Synthase Activity
And Its Inhibition In Intact L1210 Leukemia Cells In Vitro
Thymidylate synthase is one suspected site of action of the compounds. Hence, the activity of selected compounds of the present invention, measured on thymidylate synthase activity measured in vitro, is a reliable indicium of the behavior of these compounds in in vivo systems.
Mouse leukemia L1210 cells are harvested from the cell culture flasks and the cell concentration is determined. The cells are then resuspended in the desired amount of the medium to give a stock concentration 5x107 cells/mL. Series of the
38 dilution of the stock solution of the compounds to be tested are prepared (concentrations are ranged from 108 M to 10"3 M). The solution of the compound to be tested in the desired concentration is pipetted into a microcentrifuge tube and incubated at 37 °C using a shaking water bath. The reaction is started by addition of [5-3H]-2 '-deoxycytidine (10 μL, concentration of the stock solution - 10"5 M) after a 30 or 60 min. preincubation with 80 μL of the cell suspension and allowed to proceed for 30 min. in a shaking water bath at 37°C. The reaction is terminated by adding 100 μL of the 10% charcoal in 4% HC1 O4. The tubes are vigorously stirred by vortexing and then centrifuged for 10 min. in a Beckman Microfuge. The radioactivity of a 100 μL of supernatant fraction from each tube is counted in a Packard Tri-Carb (model 2450 or 3255) liquid scintillation spectrometer using a toluene based scintillation mixture. The release of tritium is expressed as a percentage of the total amount of radioactivity added. IC50 values determined from dose response curves represent the concentration of inhibitors required for 50% inhibition of the release of tritium. Table 3 below shows the results of the analysis of tritium release and determination of the IC50.
TABLE 3
Inhibition
Sample of Tritium
Code Release,
IC™ (μM)
5FUdR 0.035
L-102 0.035
L-103 0.035
L-107 > 100
L-108 > 100
L-109 > 100
L-110 6
Figure imgf000041_0001
L-111 N T
39 Example 7 in Vivo Testing of Dimers in
P388 Leukemia B16 Melanoma
A. EXPERIMENTAL
1. P388 Leukemia
B6D2F1 mice received i.p. inocula of P388 murine leukemia cells prepared by removing ascites fluid containing P388 cells from tumored B6D2F1 mice, centrifuging the cells, and then resuspending the leukemia cells in saline. Mice received 1 x 106 P388 cells i.p. on day 0. On day 1 , tumored mice were treated with the dimers or vehicle control. The route of drug administration was i.p. and the schedule selected was daily x 5. The maximum tolerated doses (MTD) was 200 mg/kg for each dimer and was determined in initial dose experiments in non-tumored mice. In the actual experiments, L-103 was given at 100 mg/kg and 50 mg/kg.
2. B16 Melanoma
B6D2F1 mice received i.p. inocula of B16 murine melanoma brei prepared from B16 tumors growing s.c. in mice (day 0). On day 1 , tumored mice were treated with the dimers or vehicle control. The route of drug administration was i.p. and the schedule selected was daily x 5. The maximum tolerated doses (MTD) was 200 mg/kg for each dimer and was determined in initial dose experiments in non-tumored mice. In the actual experiments, L-103 was given at 100 mg/kg and 50 mg/kg.
3. Survival Standard
The mean survival times of all groups were calculated, and results are expressed as mean survival of treated mice / mean survival of control mice (T/C) x 100%. A T/C value of 150 means that the mice in the treated group lived 50% longer than those of the control group; this is sometimes referred to as the increase in life span, or ILS value.
In the P388 studies, mice that survive for 30 days are considered long term
40 survivors or cures while in B16; mice that survive for 60 days are considered long term survivors or cures. The universally accepted cut-off for activity in both models, which has been used for years by the NCI, is T/C = 125. Conventional use of B16 and P388 over the years has set the following levels of activity: T/C < 125, no activity; T/C = 125-150, weak activity; T/C = 150-200, modest activity; T/C = 200-300, high activity; T/C > 300, with long term survivors; excellent, curative activity.
B. RESULTS
1. P388 Leukemia
L-103 demonstrated modest activity in the P388 leukemia in mice at all doses tested (Table 5). L-103 gave i.p. daily x 5 at doses of 100 mg/kg and 50 mg/kg resulted in T/C values of 149 and 144 respectively. Fluorodeoxyuridine (FUdR) was used as the positive drug control in this study; FUdR produced a T/C = 164 in the P388 test (Table 4). All agents were well-tolerated in this experiment; there was little or no body weight loss and no toxic deaths were recorded.
TABLE 4 L-103 vs. Murine P388 Leukemia
Weight
Change
Group n Dose (Day 7) T/C
Control (10) 0.9% Saline +9.1% 100
L-103 (10) 100 mg/kg +1.5% 149
L-103 (10) 50 mg/kg -1.6% 144
Figure imgf000043_0001
FUdR (10) 100 mg/kg -2.7% 164]
2. B16 Melanoma
L-103 demonstrated modest activity against B16 melanoma implanted in mice (Table 6). L-103 (i.p.; daily x 5) gave T/C values of 139 and 134 respectively. The
41 positive control drug FUdR resulted in modest efficacy in the B16 test; a T/C value of 135 was obtained (Table 5). All agents were well-tolerated, with little or no weight loss; no drug-related deaths occurred.
TABLE 5 L-103 vs. Murine B16 Leukemia]
Weight
Change
[Group n Dose (Day 7) T/C
Control (10) 0.9% Saline +4.9% 100
L-103 (10) 100 mg/kg +2.3% 139
L-103 (10) 50 mg/kg +6.3% 134
Figure imgf000044_0001
FUdR (10) 100 mg/kg -0.5% 135]
L-103 demonstrated modest activity against both the P388 and B16 experimental murine tumors at the two doses tested. L-103 was approximately as active as the positive control drug FUdR in the B16 test, and was somewhat less active than FUdR in the P388 test.
From the foregoing, the significance of L-sugar-based α- and β-enantiomeric nucleosides, nucleotides and their analogues as versatile, highly effective chemotherapeutic agents is apparent. Our results on derivatives of 5-FUdR show that L-5-FUdR-containing isomers are less toxic than those containing β-D-5FUdR, perhaps because they are not phosphorylated or transported as the latter. We have found that dimeric derivatives designed and prepared from α-L-5FUdR show very potent activity against P388 leukemia cells and B16 melanoma cell lines, exceeding that of β-D-5FUdR. They appear to have unusual mechanisms of action, including inhibition of telomerase.
Example 8 In Vivo Activity of Nucleoside Analogs
42 A. In Vitro Culture of the Malarial Parasite
P. falciparum, FCQ27, was maintained in culture using the techniques described by Trager & Jensen (W. Traqer and J.B. Jensen, Science, 193 673-675 (1976)). Cultures containing 2% hematocrit suspensions of parasitized human type O+ erythrocytes in RPMI 1640 medium, supplemented with 25 mM HEPES-KOH, pH 7.2, 25 mM NaHCO3 and 10% human type O+ serum (v/v) are maintained in modular incubator chambers at 37° C in a gas mixture of 5% 02, 5% CO2 and 90% N2. The isolate of P. falciparum used in these experiments was FCQ27, routinely maintained in synchronized or asynchronous in vitro cultures at low hematocrit.
B. In Vitro Toxicity against P. falciparum
The potential toxicity of nucleoside analogues against P. falciparum in culture was tested in microtitre plates over the range of drug concentrations for 24 hours. The procedures for monitoring parasite viability is well established (A.M. Gero, H.V. Scott, W.J. O'Sullivan and R.I. Christopherson, Mol. Biochem. Parasitol. 34, 87-89 (1989)) and is based on radiolabelled hypoxanthine or isoleucine incorporation. The incorporation of [G-3H]hypoxanthine into the nucleic acids of P. falciparum was used to assess the viability of the parasite in vitro. Microculture plates were prepared with each well containing 225μl of a 2% hematocrit culture of asynchronous parasited erythrocytes (1% parasitized cells). Each plate, containing varying concentrations of the drug to be studied (up to 200 μM final concentration for initial screen), was incubated for 24 h at 37° C in a gas mixture of 5% O2, 5% CO2 and 90% N2, at which point [G-3H] hypoxanthine was added to each well and the incubation continued under identical conditions for a further 18-20 h. The control infected cells (i.e. without drug), routinely reached a parasitemia of 6-8% before harvesting. Expediency was aided by 96-well plate counter using lactate dehydrogenase for the drug susceptibility assay (L.K. Basco, F. Marguet, M.T. Makler and J. Lebbras, Exp. Parasitol. 80, 260-271 (1995); M.T. Makler and D.J. Hinrichs; Am. J. Trop. Med. Hyg. 48, 205-210 (1993)). This assay gave the identical results to the hypoxanthine technique. In addition, for each experiment, microscopic counting of Giemsa stained thin slides was used as a control.
43 C. Transport and Metabolism in P. falciparum infected erythrocytes
The metabolism of the L-nucleoside conjugates was studied by HPLC analysis. The primary aim was to determine their ability to be catabolized by parasite purine salvage enzymes. Some effect on the purine metabolic pools was also observed.
For each HPLC determination 200 μL of packed cells of 80-90% trophozoite infected cells were used. These were isolated from in vitro cultures by synchronization of the parasites in in vitro cultures using sterile D-sorbitol (L. Lambros and J.P. Vanderberg, Parasitol. 65, 418-420 (1979)) followed by separation of the trophozoites from non infected erythrocytes by Percoll gradients as described previously (A.M. Gero, H.V. Scott, W.J. O'Sullivan and R.I. Christopherson, Mol. Biochem. Parasitol. 34, 87-89 (1989)). Trophozoites were incubated at 37 °C for 2 hours with each compound to be tested. Compounds were incubated with both whole infected cells as whole and lyzed uninfected normal erythrocytes to determine: a) entry to the cell (whether they were transported); b) the metabolic effect within the cell (was the compound metabolized); c) the capacity of broken or lyzed cells to catabolize the compound which may not be able to enter the unbroken cell (i.e. if the compound was transported into the cell, would it be metabolized to the active form).
Drug incubation was terminated by centrifugation through silicon oil using the method of Upston and Gero (J.M. Upston and A.M. Gero, Biochem. Biophys. Acta. 1236, 249-258 (1995)). This procedure separated intact trophozoites from extracellular non-transported drug solution.
The metabolism of nucleosides with potential chemotherapeutic activity was assessed by the analysis of cytoplasmic samples by reverse phase ion-pair high performance liquid chromatography (R.S. Toguzov, YN. Tikhonov, A.M. Pimenov, V. Prokudin, Journal of Chromatography, I. Biomedical Appl. 434, 447-453 (1988)). Nucleotides, nucleosides and bases were separated by this HPLC method.
The transport and metabolism of purine nucleosides differ considerably between the normal human erythrocyte and human erythrocytes which have been
AA infected with Plasmodium falciparum. The malaria parasite is unable to synthesize purines de novo and so therefore must rely on salvage pathways to obtain purines it requires for growth and division (L.W. Scheibel & T.W. Sherman, In: Malaria: Principles and practice of Malariology (W.H. Wemsdorfer & I. McGregor, Eds.) V. 1 , 234-242 (1988)). Additionally, normal human erythrocytes do not contain significant levels of pyrimidine nucleotides (E. Szabodos & R.I. Christopherson, Biochem. Edu. 19, 90-94 (1991 )), and the parasite is unable to obtain pyrimidine bases by salvage pathways and again has to rely on de novo synthesis (L.W. Scheibel & T.W. Sherman, In: Malaria: Principles and practice of Malariology (W.H. Wemsdorfer & I. McGregor, Eds.) V. 1 , 234-242 (1988)). These modifications to the metabolic pathways of the infected erythrocytes, along with modifications of their transport system, represent significant variations from normal erythrocytes and may present an opportunity for the use of selectively toxic compounds against the parasites.
Nucleosides have attracted researchers as potential therapeutic agents. Naturally occurring nucleosides are usually in the β-D configuration. Therefore most of nucleoside analogues designed for the treatment of cancer, viral and parasitic diseases have been synthesized in this stereochemical configuration. Recent discoveries in our laboratories at the University of Georgia, the University of Iowa and at Yale University, as well as at universities in France and Italy, have confirmed that most L-nucleosides exhibit low toxicity because normal cells do not utilize them for building RNA or DNA and don't metabolize them.
Recently, Dr. Gero and her coworkers discovered that the nonphysiological β-L-adenosine can be selectively transported into an erythrocyte infected with P. falciparum (A.M. Gero & J.M. Upston, In: Pyrine & Pyrimidine Metabolism in Man VIII (A. Sahota & M. Taylor, Eds) Plenum Press, NY, 495-498 (1995). Normal erythrocytes and other cell types are completely impermeable to this compound.
During the Phase I study, we used this unique ability of the non-natural nucleoside analogues for selective transport to the malaria infected cells to create a novel synthetic L-nucleoside based class of non-toxic antimalarial agents. Our working hypothesis was based on the design and biological evaluation of novel chemical entities which would consist of both 5-fluorodeoxyuridine (FUdR), a known
AS inhibitor of thymidylate synthase, and an L-nucleoside or its derivatives. The number of "dimers" consisting of α-or β-L isomeric modification of physiological nucleosides or their derivatives was conjugated with FUdR by phosphate or pro-phosphate linkage. Along with anticancer activity, FUdR has a potential as an antimalarial agent (S.A. Queen, D.L. Vander Jagt & P. Reyer, Antimicrobial Agents & Chemotherapy. 34, 1393-1398 (1990). Unfortunately, FUdR's toxicity limits its use. In theory, combining FUdR with an L-nucleoside unit would result in an entity that could selectively transport an active component to infected cells while having no effect on normal cells.
During Phase I research a total of 42 L-nucleoside analogs were screened in an in vitro assay against P. falciparum. These compounds are shown in Figure 7. From these forty-two compounds, 31 were available for screening from Lipitek International's library and 11 were specifically synthesized for the purpose of this project. The detailed synthesis of 11 L-nucleoside conjugates is described in the Methods and Procedures. They were prepared in 100 mg scale and were fully characterized by analytical methods (NMR, HPLC, mass spectra, TLC). The forty-two compounds tested were representative of L-nucleoside monomers or 4 different types of L-nucleosides conjugates. The conjugates tested were: a) dinucleoside phosphates, b) dinucleoside phosphorothioates, c) SATE derivatives of L-nucleosides, and d) L-nucleoside conjugates of nitrobenzylthionosine (NBMPR). It should be emphasized that even more diversification resulted from utilizing characteristic to nucleosides 3' to 5' versus 5' to 3' phosphodiester linkages as well as variations of purines and pyrimidines in both parts of the dimers.
The biological screen involved evaluation of the compounds against the protozoan P. falciparum in in vitro culture. The range of drug concentrations was used independently by two assays. One, radiolabelled hypoxanthine incorporation into the nucleic acid of P. falciparum, and the other, more expedient assay, a 96-well plate susceptibility assay using lactate dehydrogenase. Both assays gave identical results. In addition, microscopic counting of Giemsa stained thin slides was used as a control. The results of the biological assays are presented in Table 1. Examples of experimental curves are attached as Appendix 2. The biological tests
A6 were done at several concentrations. The highest concentration was 200 μM, the compounds were considered active at concentrations less than 40μM.
Discussions In vitro activity
A careful analysis of the data presented in Table 6 (below) indicates that nine (9) analogs from 42 screened had IC50 less than 40μM (for the structure of the tested compounds see Figure 14). The most active representative of dinucleoside phosphates were L-101 , L-103, L-110, L-111 , L-113, L-133 and L-138.
Table 6 Results of the in vitro testing.
N CODE COMPOUND IC50, μM
1. L-101 [β-D],-FUdR 15
2. L-103 [α-L,β-D]-FUdR 20
3. L-103 thio [α-L,β-D]-FUdR, S=P-0" >200
4. L-109 [β-L],-FUdR >200
5. L-110 [β-L, β-D]-FUdR 20
6. L-111 α-L-dC, β-D-FUdR 38
7. L-113 β-L-dC, β-D-FUdR 17
8. L-117 β-L-dU, β-D-FUdR 35
9. L-117 thio β-L-dU, β-D-FUdR S=P-0" >200
10. L-125 α-L-dA, β-D-FUdR 60
11. L-128 [β-D, β-D-FUdR] S=P-0" 1.5
12. L-133 β-L-dG, β-D-FUdR 14
Figure imgf000049_0001
13. L-138 β-L-dA, β-D-FUdR 5
A7 14. L-138-thio β-L-dA, β-D-FUdR, S=P-0" 100
15. L-144 β-D-FUdR, β-L-A 140
16. L-145 β-L-dU, NBMPR >200
17. L-146 α-L-dT, NBMPR >200
18. L-147 NBMPR, MP Solubility problem
19. NBMPR NBMPR 100
20. GCI 1007 α-L-erythrofuranosyl-5-fluorouracil >200
21. GCI 1018 α-L-arabinofuranosyl adenine >200
22. GCI 1027 α-L-FUdR >200
23. GCI 1030 β-L-G >200
24. GCI 1032 β-L-A >200
25. GCI 1033 β-L-l >200
26. GCI 1034 β-L-mercapto-G >200
27. GCI 1036 β-L-Da >200
28. GCI 1037 β-L-dl >200
29. GCI 1066 α-L-A >200
30. GCI 1069 α-L-dA >200
31. GCI 1070 β-L-dG >200
32. GCI 1077 β-L-ddA >200
33. GCI 1079 α-L-ddA >200
34. GCI 1085 N6-methyl-β-L-A >200
35. GCI 1076 6-thio-β-L-purine >200
36. B01 β-D-FUdR 3'SATE 100
37. B02 β-D-FUdR 5'SATE 60
38. B03 β-D-FUdR 3"-5'SATE 6
39. B04 β-L-FUdR 5'SATE 200
40. B05 β-L-FUdR 3'-5' SATE Solubility problem
Figure imgf000050_0001
41. B06 α-L-FUdR 5'SATE 150
48 42. B07 α-L-FUdR 3'-5'SATE Solubility
Figure imgf000051_0001
problem
The 14 L-nucleoside monomers in α- and β- forms and even α-L-FUdR showed no activity against P. falciparum. Because of that, further research on monomers was halted (see Table 6).
The dimer containing only the "non-natural" isomeric form of nucleoside (L-109) did not exhibit any activity.
Careful analysis of the data in Table 6 indicates that β-D-isomer of FUdR is the active component of the dimer molecules. The position of the active component in the dimer is important. The β-D-FUdR needs to be connected to the 3'-OH end of the L-nucleoside through a phosphodiester linkage to its 5'-OH. Compounds which are linked through 3'-OH of FUdR are much less active (see Table 7). This indicates that the substitution pattern of β-D-FUdR is critical for the activity of the dimers and most probably the mechanism involves thymidylate synthase inhibition. It is well known that TS inhibitors of FUdR have very rigid structural requirements and do not allow for any substitution at the 3' end.
49 Table 7. The activity of the L-nucleoside containing dimers versus position of FUdR linkage
5' 3'
Compound IC*. Compound IC*. μM μM
L-101 ([β-D]2-FUdR) 15 L-144 (β-D-FUdR, β-L- 140 A)
L-103 (α-L-FJdR, β-D-FUdR) 20
L-110 (β-L-FUdR, β-D-FUdR) 20
L-111 (α-L-dC, β-D-FUdR) 38
L-113 (β-L-dC, β-D-FUdR) 17
L-125 (α-L-dA, β-D-FUdR) 60
L-133 (β-L-dC, β-D-FUdR) 14
L-138 (β-L-dA, β-D-FUdR) 5
Figure imgf000052_0001
Table 8. The activity of the dimers versus chemical configuration of the L-nucleoside
α-L β-L
Compound IC50, Compound IC50, μM μM
L-103 (μ-L-FUdR) 20 L-110 (β-L-FUdR) 20
L-111 (α-L-dC) 38 L-113 (β-L-dC) 17
Figure imgf000052_0002
L-125 (α-L-dA) 60 L-138 (β-L-dA) 5
In the case of purine nucleoside, the attachment of the α-L nucleoside to β-D-FUdR monomer reduces the dimer activity in comparison with dimers containing the β-L unit (see Table 8, L-125 and
50 L-138). In the case of pyrimidine nucleosides there is no obvious difference in the activity (L-103 & L-110, L-111 & L-113).
Table 9. The activity of the dimers versus nature of the linkage between two nucleosides analogs
Phosphate "bridge" ICso, Phosphorothioate "bridge" IC50, o=p-o μM S=P-0 μM
L-101 ([β-D],-FUdR) 15 L-128 ([β-D]7-FUdR) 1.5
L-103 ([α-L,β-D]-FUdR 20 L-103 ([α-L,β-D]-FUdR >200
L-117 (β-L-dU, β-D-FUdR) 35 L-117 (β-L-dU, β-D-FUdR) >200
L-138 (β-L-da, β-D-FUdR) 5 L-138 (β-L-dA, β-D-FUdR) 100
Figure imgf000053_0001
The different activity of the dimers is dependent on the structure of the second nucleoside.
The following plausible pathways for metabolic activation and/or mode of action of the dimer molecules tested are that:
(1 ) Dimer may act as a new chemical entity without hydrolysis of the phosphate or pro-phosphate bond between the two monomeric units;
(2) Hydrolysis to L-nucleoside and FUdR nucleotide may occur, in which case the dimer is a prodrug. The L-nucleoside is used for protection and to increase the bioavailability of β-D-FUdR monophosphate. It is also important to note that hydrolysis can take place intracellularly as well as outside the cell. In the last decade, monumental efforts have been directed toward the synthesis of oligonucleotide analogs with altered phosphodiester linkage. The goal was to improve the stability of duplex and triplex
51 formation, to improve the cellular uptake and to decrease the rate of degradation of oligonucleotides by endo and exo nucleases which cleave the phosphodiester linkage. We selected one such chemical modification for our study. As a consequence, several dimers with phosphorothioate linkage between two nucleosides were synthesized and tested. The phosphorothioate comprises a sulfur-for-oxygen substitution at phosphorus of the phosphodiester linkage (for the structure of the corresponding dimers see Appendix 1 ). It has been shown (M. Matsukura, K. Shinozuka, G. Zon, H. Mitsuya, M. Reitz, J.S. Cohen, L.M. Neckers, Proc. Natl. Acad. Sci. USA. 84, 7706 (1987)) that the S homologues are more resistant to cellular nucleases and are readily taken up by cells. Several oligonucleotides of this type are currently in clinical studies (ISIS Pharmaceuticals and others).
Table 10. The activity of β-D-FUdR and some possible products of its metabolism
COMPOUND IC50> μM β-D-FUdR 34 β-D-5'-FUdRmP 50
Figure imgf000054_0001
5FUracil 6
The replacement of the phosphate linkage by the phosphorothioate bond in the dimer, containing two β-D-FUdR units, increases the activity of the compounds by a factor of 10 (see Table 9, data for L-101 & L-128). The only active phosphorothioate analog appears to be compound L-128. The activity of L-128 is greater in comparison with all possible products of hydrolysis (see Table 10). Moreover, L-128 was the most active
52 compound tested.
Table 11. The activity of the SATE derivatives of FUdR
Compound ID50, μM β-D-FUdR 34 β-D-FUdR monophosphate 50
B01 (β-D-FUdR 3' SATE) 100
B02 (β-D-FUdR 5* SATE) 60
B03 (β-D-FUdR 3',5' SATE) 6 β-L-FUdR >200 β-L-FUdR monophosphate N/A
B04 (β-L-FUdR 5' SATE) 200
B05 (β-L-FUdR 3',5' SATE) Solubility problem α-L-FUdR >200 α-L-FUdR monophosphate N/A
B06 (α-L-FUdR 5* SATE) 150
Figure imgf000055_0001
B07 (α-L-FUdR 3',5' SATE) Solubility problem
The introduction of the phosphorothioate bond into molecules of dimers containing "non-natural" nucleoside isomer was not successful: the activity of the compounds was reduced dramatically (see Table 9, data for L-103, L-117 & L-138). As was discussed before, one of the possible mechanisms of dimer action is the participation in the metabolic pathways of the whole non-hydrolyzed molecule. In this case the increasing of the dimer stability by the introduction of the phosphorothioate linkage results in the increasing of the activity of L-101. For the dimers containing the
53 "non-natural" isomeric modification of the nucleoside the metabolism of whole non-hydrolyzed molecule is probably impossible.
It is well established that most of the nucleoside analogs are dependent in kinase-mediated activation to generate the bioactive nucleotide and ultimately, the nucleoside triphosphate (C. Periqaud, G.
Gosselin, J.L Imbach, Nucleoside Nucleotides. 11 , 903 (1992)). Activation takes place in the cytosol after nucleoside uptake and involves three successive viral and/or cellar kinases, the first one being highly specific (M.C. Starnes, Y.C. Cheng, J. Biol. Chem. 262, 988 (1987)). One possibility to improve the efficiency of the nucleoside analog is a therapeutic agent could be to bypass the phosphorylation step. Unfortunately, nucleoside monophosphates themselves, due to their polar nature, are not able to cross the cell membrane efficiently (K.C. Leibman, C.J. Heidelberg, J. Biol. Chem. 216, 823 (1995)). Hence the idea of temporarily masking or reducing the phosphate negative charges with neutral substituents, thereby forming more lipophilic derivatives which would be expected to revert back to the nucleoside mono-phosphate once inside the cell.
One of the possible structural modifications for the kinase bypass is the use of the bis-S-acetylthioethyl (SATE) derivatives pioneered by
J.-L. Imbach (I. Lefebvre, C. Perigaud, A. Pompon, A.M. Auberth, J.L. Grardet, A. Kim, G. Gosselin and J.L. Imbach, J. Med. Chem. 38, 3941-3950 (1995); C. Perigaud, G. Gosselin, I. Lefebvre, J.L. Girardet, S. Benzaria, I. Barber and J.L. Imbach, Bio. Org. Med. Chem. Lett. 3, 2521-2526 (1993)). Several SATE derivatives of FUdR isomers were synthesized and tested their in vitro activity against P. falciparum. The obtained results are listed in Table 11.
It should be emphasized that all of the SATE derivitization was performed on monomers of FUdR varying the conformation. Thus
54 derivatives of α- and β D and L-FUdR were prepared. Three types of SATE analogs were produced, a) decorated at 5' of the nucleoside, b) decorated at 3' of the nucleoside, and c) decorated at both 3' and 5' of the nucleoside resulting in disubstitution. Fifteen L-nucleoside dimers (L-101 , L-103, L-103A, L-107, L-110, L-111 , L-112, L-114, L-117, L-120, L-122,
L-124, L-125, L-133 & L-138) from Lipitek's library were submitted for in vitro screen to the U.S. Army Antimalarial Test Program (for the structures of the compounds, see Figure 7). The compounds have been tested for their activity against two P. falciparum strains: D6 (chloroquin non-resistant) and W2 (chloroquin resistant). Seven (7) of the tested compounds exhibited activities below 40 μM against both strains of P. falciparum. The most active dimers were L-101 , L-110, L-112, L-117, L-133 & L-138.
The transport and metabolism study It has been established that transport and uptake in parasite invaded cells is different from that of normal blood erythrocytes (A.M. Gero & A.M. Wood, In: Pyrine & Pyrimidine Methabolism in Man VII, Part A. (R.A. Harkness et al., Eds) Plenum Press, NY, 169-172 (1991 )). Invasion by the malaria parasite comprises the cell membrane, allowing penetration of unnatural substances of various size and shape, whereas normal cells are very selective in uptake. It was shown that L-nucleosides and their derivatives easily penetrate invaded cells, while they have a very slow rate of uptake into normal cells, if they enter at all. In order to obtain preliminary data on transport, uptake and metabolism, the HPLC method was used to analyze the following 10 Lipitek compounds: L-101 ,
L-103, L-109, L-111 , L-117, L-133, L-138, GCI 1007, GCI 1027, GCI 1069.
55 HPLC retention times for standard compounds purchased from Sigma is presented in Table 12.
Table 12. HPLC Retention Time for the Standard Compounds
Compound R.t., min Compound R.t., min
Nucleobase Nucleotide
Adenine 4.93 5'AMP 16.56
Guanine 5.38 3'AMP 19.46
Uracil 4.37 5'ADP 23.89
Hypoxanthine 5.59 5'-ATP 30.09
Nucleoside 5'GMP 15.24
Adenosine 12.47 5'-GDP 23.13
Guanosine 9.96 5'GTP 29.01
Inosine 8.88 5'-UMP 14.85
Thymidine 12.36 FUdRMP 16.40
2'-Deoxyadenosine 12.29
2'-Deoxyguanosine 11.03
2'-Deoxyuridine 7.41
2'-Deoxycytidine 8.25
Figure imgf000058_0001
FUdR 10.21
Table 13. HPLC Retention Time of Lipitek's Compounds (Trophozoite Incubations)
Compound Neat Injection Unmetabolized Metabolic Peak Product
Figure imgf000058_0002
L-138 18.17, 18.89 18.26 16.93, 15.73
56 L-133 16.72 17.03 15.65
L-101 19.05 19.01 10.62
L-103 18.31 18.25 _
L-117 17.41 17.61 _
L-111 15.69 15.69 _
L-109 16.36 _ _
GCI 1027 10.21 10.61 _
GCI 1007 12.61 12.42 _
Figure imgf000059_0001
GCI 1069 12.29 - 9.65
These compounds were chosen for the identification of possible metabolites. In this experiment the compounds were incubated with both whole infected cells, and with whole and lysed uninfected cells, followed by the separation of unreacted compound and HPLC analysis. The results are presented in Table 13: Column 1 shows the retention times of the original compound (not incubated with any cells).
Column 2 shows the retention times of the original compound remaining after incubation with whole parasite infected cell. Column 3 shows the metabolic products i.e. new peaks due to conversion of the original compound or alteration in the natural purine or pyrimidine profile of the infected cell.
All nucleosides monophosphate dimers containing β-D-FUdR unit in combination with any L-nucleosides (L-101 , L-103, L-111 , L-117, L-133, and L-138) as well as tested L-nucleoside monomer analogs (GC1 1007, GC1 1027 & GC1 1069) entered the infected cells. All these compounds were toxic against P. falciparum. The L-109, combination of two L-dimers,
57 could not enter the infected cell, and was also not toxic.
Compounds L-101 , L-133 & L-138 appear to be metabolized by the infected cells, each producing at least one new peak (see Table 13). It is possible that L-138 and L-133 may be cleaved to a nucleotide and nucleoside.
None of the above 10 compounds were found to enter normal erythrocyte. Metabolism of any of the above compounds did not occur in lysates of human erythrocytes or lymphocytes. So even if the compounds were able to get into the normal cells, the normal cells cannot metabolize them into active ingredients. This underscores again the low toxicity and the selectivity of the L-nucleoside conjugates disclosed and claimed in this Application.
Example 9 Synthesis of N6-Benzoyl-3'-deoxy-β-D-adenosine To a stirring solution of 3'-deoxyadenosine (2.0 g, 7.96 mmol) in pyridine (80 ml) chilled in an ice bath, CISiMe3 (5.0 ml, 39.8 mmol) was added dropwise and stirred for 30 minutes. Benzoyl chloride (3.7 ml, 31.84 mmol) was then added dropwise and the reaction mixture was stirred at room temperature for two hours. This was cooled in an ice bath and water (16 ml) was added dropwise. 15 minutes later concentrated
NH4OH (16 ml) was added to give a solution approximately 2M in ammonia. After 30 minutes the solvent was evaporated and the residue was dissolved in water and washed with ether. The water layer was concentrated and the compound was crystallized from water as white solid (2.32 g. 82%).
58 Example 10 Synthesis of N6-Benzoyl-5'-O-(di p-methoxytrityl)-3'-deoxy-β-D-adenosine
To a solution of compound N6-Benzoyl-3'-deoxy-β-D-adenosine 1 (2.32 g, 6.53 mmol) in pyridine (100 ml) was added 4,4'-dimethoxytrityl chloride (3.32g, 9.79 mmol) and DMAP (0.24 g, 1.96 mmol) and stirred at room temperature for 2 hours under argon. To complete the reaction, additional DMTCI (0.5 g) was added and stirred for another 2 hours. The reaction was quenched with the addition of MeOH (5 ml) and the solvent was evaporated. The residue was dissolved in EtOAc, washed with water,
NaHCO3 and brine. After drying over Na2SO4, the EtOAc layer was evaporated and the crude compound was purified on a silica gel column using 80% EtOAc/CHCI3 as solvent to give pure compound 2 (4.33g, 83%) as a white foam.
Example 11
Synthesis of N6-Benzoyl-2'-O-acetoxy-β-D-3'-deoxyadenosine
To a solution of N6-Benzoyl-5'-O-(di p-methoxytrityl)-3'-deoxy-β-D-adenosine (4.3 g, 6.58 mmol) in pyridine (100 ml) acetic anhydride (1 ml, 9.87 mmol), and DMAP (0.08 g, 0.65 mmol) was added and stirred at room temperature for 15 minutes. Then the solvent was evaporated and the residue was dissolved in EtOAc, washed with water, NaHCO3, brine and dried over NA2SO4. After the evaporation of EtOAc, then the crude material was dissolved in 80% AcOH (50 ml) and stirred at room temperature for one hour. Then the solvent was evaporated and coevaporated with tolune and purified on a silica gel column using 3-5% MeOH/CHCI3 to give pure N6-Benzoyl-2'-O-acetoxy-β-D-3-deoxyadenosine (2.11 g, 81 %) as a foam.
59 Example 12 Synthesis of β-L-dU. Cordvcepin dimer (L-150) β-L-dU (1.0 g, 4.38 mmol) was dissolved in dry pyridine (50 ml), to this solution was added 4,4'-dimethoxytrityl chloride (1.78 g, 5.25 mmol) and DMAP (0.1 g, 0.87 mmol). This was stirred under argon at room temperature for 2 hours and quenched with MeOH (5 ml). The solvent was evaporated, the residue was dissolved in EtOAc, washed with water, NaHCO3 and brine. After drying and evaporation of the solvent, the crude material was purified on a silica gel column using 60-80% EtOAc/CHCI3 as solvent to give pure 5'-O Dimethoxytrityl-β-L-2'-deoxyuridine (2.2 g,
94.8%) as white foam.
Dimethoxytrityl-β-L-2'-deoxyuridine (1.5 g, 2.83 mmol) was dissolved in anhydrous dichloromethane (50 ml). N, N-diisopropylethylamine (2.0 ml, 11.3 mmol) was added uner argon followed by 2'-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.82 ml,
3.68 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated. The residue was dissolved in 80% EtOAc/Et3N (75 ml) and washed with water, NaHCO3 and brine. The organic layer was evaporated and purified on a short silica gel column using a mixture of EtOAc, CH2CI2 and ET3N (40:50: 10) to give
5'-O-Dimethoxytrityl-β-L-2'-deoxyuridine-3'-N, N-diisopropylcyanoethyl phosphoramidite in quantitative yield.
5'-O-Dimethoxytrityl-3'-[O-(2'-O-acetyl)-N6-benzoyl-β-D-3'-deoxy adenosinyl]-2'-deoxy-β-L-uridine cyanoethyl phosphite ester (7). To a solution of compound
5'-O-Dimethoxytrityl-β-L-2'-deoxyuridine-3'-N, N-diisopropylcyanoethyl phosphoramidite (2.83 mmol) in anhydrous acetonitrile (60 ml), N6-Benzoyl-2'-O-acetoxy-β-D-3-deoxyadenosine (1.12 α. 2.83 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon. To
60 this solution, sublimed 1 H-tetrazole (0.6 g, 8.5 mmol) was added and stirred over night. The solvent was evaporated and the residue was triturated with 70% EtOAc/ether and filtered. The filtrate was evaporated to give 5'-O-Dimethoxytrityl-3'-[O-(2'-O-acetyl)-N6-benzoyl-β-D-3'-deoxy adenosiny!]-2'-deoxy-β-L-uridine cyanoethyl phosphite ester as a foam and this was used in the next step without further purification.
The 5'-O-Dimethoxytrityl-3'-[O-(2'-O-acetyl)-N6-benzoyl-β-D-3'-deoxy adenosinyl]-2'-deoxy-β-L-uridine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (1.0 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate. The solvent was evaporated and the residue was dissolved in EtOAc and washed with water, NaHCO3 and brine. EtOAc layer was evaporated and the residue was dissolved in 80% acetic acid/water solution (40 ml) and stirred for 1 hour. Then the solvent was evaporated and the crude product was purified on a silica gel column using 8-15% MeOH/CHCI3 as solvent to give pure (2'-Acetoxy-N6-benzoyl-3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyuridinyl cyanoethyl phosphate ester (0.75 g) as a foam.
The dimer (2'-Acetoxy-N6-benzoyl-3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyuridinyl cyanoethyl phosphate ester (0.75 g) was treated with ammoniun hydroxide solution (100 ml) over night. The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH4HCO3 buffer (0.05-0.2M). The pure fractions were collected and lyophillized to give pure 3'-O-(3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyuridine (L-150)(0.486 g) as
61 white solid.
Example 13 Synthesis of β-L-dA. Cordvcepin dimer (L-151) To a stirring solution of 2'-deoxy-β-L-adenosine (2.05 g, 8.16 mmol) in pyridine (75 ml) chilled in an ice bath, CISiMe3 (5.17 ml, 40.8 mmol) was added dropwise and stirred for 30 minutes. Benzoyl chloride (4.7 ml, 40.8 mmol) was then added dropwise and the reaction mixture was stirred at room temperature for two hours. This was cooled in an ice bath and 0 water (15 ml) was added dropwise. 15 minutes later concentrated NH4OH
(15 ml) was added to give a solution approximately 2 M in ammonia. After 30 minutes the solvent was evaporated and the residue was dissolved in water and washed with ether. The water layer was concentrated and the N6-benzoyl-2'-deoxy-β-L-adenosine was crystallized from water as white 5 solid (2.48 g, 85.8%).
To a solution of N6-benzoyl-2'-deoxy-β-L-adenosine (2.48g, 6.98 mmol) in pyridine (100 ml) was added 4,4'-dimethoxy trityl chloride (3.55 g, 10.47 mmol) and DMAP (0.25 g, 2.09 mmol) and stirred at room temperature for 2 hours under argon. To complete the reaction, additional o DMTCI (1.3 g) was added and stirred for another 2 hours. The reaction was quenched with the addition of MeOH (5 ml) and the solvent was evaporated. The residue was dissolved in EtOAc, washed with water, NaHCO3 and brine. After drying over Na2SO4, the EtOAc layer was evaporated and the crude compound was purified on a silica gel column 5 using 3-5% MeOH/CHCI, as solvent to give pure
N6-benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy-β-L-adenosine (3.42 g, 74.5%) as pale yellow foam.
N6-benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy-β-L-adenosine (1.64 g, 2.5 mmol) was dissolved in anhydrous dichloromethane (50 ml).
62 N,N-diisopropylethylamine (1.75 ml, 10.0 mmol) was added under argon followed by 2'-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.8 ml, 3.25 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated. The residue was dissolved in 80% EtOAc/Et3N (75 ml) and washed with water, NaHCO3 and brine. The organic layer was evaporated and purified on a short silica gel column using a mixture of EtOAc, CH2CL2 and Et3N (40:50:10) to give
N6-Benzoyl-5'-O-(dimethoxytrityl)-β-L-2'-deoxyadenosine-3'-N,N-diisoprop ylcyanoethyl phosphoramidite in quantitative yield. 0 To a solution of
N6-Benzoyl-5'-O-(dimethoxytrityl)-β-L-2'-deoxyadenosine-3'-N,N-diisoprop ylcyanoethyl phosphoramidite (2.5 mmol) in anhydrous acetonitrile (60 ml), N6-Benzoyl-2'-O-acetoxy-β-D-3'-deoxyadenosine (0.94 g, 2.36 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon. 5 To this solution, sublimed 1 H-tetrazole (0.5 g, 7.2 mmol) was added and stirred over night. The solvent was evaporated and the residue was triturated with 70% EtOAc/ether and filtered. The filtrate was evaporated to give N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-[O-(2'-O-acetyl)-N6-benzoyl-β-D-3-de o oxy adenosinyl]-2'-deoxy-β-L-adenosine cyanoethyl phosphite ester as a foam and this was used in the next step without further purification.
The dimer N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-[O-(2'-O-acetyl)-N6-benzoyl-β-D-3-de oxy adenosinyl]-2'-deoxy-β-L-adenosine cyanoethyl phosphite was 5 dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.63 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate. The solvent was evaporated and the residue was dissolved in EtOAc and
63 washed with water, NaHCO3 and brine. EtOAc layer was evaporated and the residue was dissolved in 80% acetic acid/water solution (50 ml) and stirred for 1 hour. Then the solvent was evaporated and the crude product was purified on a silica gel column using 5-10% MeOH/CHCI3 as solvent to give pure
(2'-Acetoxy-N6-benzoyl-3'-deoxy-β-D-adenosinyl)-N6-benzoyl-β-L-2'-deoxy adenosinyl cyanoethyl phosphate ester (0.97 g) as a foam.
The dimer (2'-Acetoxy-N6-benzoyl-3'-deoxy-β-D-adenosinyl)-N6-benzoyl-β-L-2'-deoxy adenosinyl cyanoethyl phosphate ester (0.97 g) was treated with ammonium hydroxide solution (100 ml) over night. The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH4HCO3 buffer (0.05 - 0.2 M). The pure fractions were collected and lyophillized to give pure compound 3'-O-(3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyadenosine (L-151 ) (0.55 g) as white solid.
Example 14 Synthesis of α-L-dU, Cordvcepin dimer (L-152) α-L-dU (1.04 g, 4.5 mmol) was dissolved in dry pyridine (50 ml), to this solution was added 4, 4'-dimethoxytrityl chloride (2.4 g, 6.86 mmol) and DMAP (0.11 g, 0.91 mmol). This was stirred under argon at room temperature for 2 hours and quenched with MeOH (5ml). The solvent was evaporated, the residue was dissolved in EtOAc, washed with water, NaHCO3 and brine. After drying and evaporation of the solvent, the crude material was purified on a silica gel column using 3-5% MeOH/CHCI3 as solvent to give pure 5'-O-Dimethoxytrityl-α-L-2'-deoxyuridine (2.4 g., 99%) as white foam. δ'-O-Dimethoxytrityl-α-L^'-deoxyuridine (1.73 g, 3.26 mmol) was
6A dissolved in anhydrous dichloromethane (30 ml), N, N-diisopropylethylamine (2.3 ml, 13.04 mmol) was added under argon followed by 2'-cyanoethyl-N,N-diisopropylchlorophosphoramidite (0.95 ml, 4.23 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated. The residue was dissolved in 80% EtOAc/Et3N (75 ml) and washed with water, NaHCO3 and brine. The organic layer was evaporated and purified on a short silica gel column using a mixture of EtOAc, CH2CL2 and Et3N (40:50:10) to give 5'-O-Dimethoxytrityl- α-L-2'-deoxyuridine-3'-N, N-diisopropylcyanoethyl phosphoramidite (2.26 g, 95%) as a foam.
To a solution of 5'-O-Dimethoxytrityl- α-L-2'-deoxyuridine-3'-N, N-diisopropylcyanoethyl phosphoramidite (2.26 g, 3.09 mmol) in anhydrous acetonitrile (60 ml), N6-Benzoyl-2'-O-acetoxy-β-D-3'-deoxyadenosine (1.35 g, 3.4 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon. To this solution, sublimed 1 H-tetrazole (0.65 g, 8.5 mmol) was added and stirred over night. The solvent was evaporated and the residue was triturated with 70% EtOAc/ether and filtered. The filtrate was evaporated to give 5'-O-Dimethoxytrityl-3'-[O-(2'-O-acetyl)-N6-benzoyl-β-D-3'-deoxyadenosin yl]-2'-deoxy-α-L-uridine cyanoethyl phosphite ester as a foam and this was used in the next step without further purification.
The dimer 5'-O-Dimethoxytrityl-3'-[O-(2'-O-acetyl)-N6-benzoyl-β-D-3'-deoxyadenosin yl]-2'-deoxy-α-L-uridine cyanoethyl phosphite ester was dissolved in THF
(24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.7 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate. The solvent was evaporated
65 and the residue was dissolved in EtOAc and washed with water, NaHCO3 and brine. EtOAc layer was evaporated and the residue was dissolved in 80% acetic acid/water solution (50 ml) and stirred for 1 hour. Then the solvent was evaporated and the crude product was purified on a silica gel column using 8-15% MeOH/CHCI3 as solvent to give pure
(2'-Acetoxy-N6-Benzoyl-3'-deoxy-β-D-adenosinyl)-α-L-2'-deoxyuridinyl cyanoethyl phosphate ester (1.29 g) as a foam.
[3O-(3'-deoxy-β-D-adenosinyl)-α-L-2'-deoxyuridine (6) (L-152)] The dimer (2'-Acetoxy-N6-Benzoyl-3'-deoxy-β-D-adenosinyl)-α-L-2'-deoxyuridinyl cyanoethyl phosphate ester (1.29 g) was treated with ammonium hydroxide solution (100 ml) over night, The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH4HCO3 buffer (0.05-0.2M). The pure fractions were collected and lyophillized to give pure
[3'-O]-(3'-deoxy-β-D-adenosinyl)-α-L-2'-deoxyuridine (L-152) (0.856 g) as white solid.
Example 15 Synthesis of β-L-dC, Cordvcepin dimer (L-153) To a solution of β-L-dCBz (1.7 g, 5.22 mmol) in pyridine (100 ml) was added 4, 4'-dimethoxy trityl chloride (2.65 g, 7.83 mmol) and DMAP (0.13 g, 1.04 mmol) and stirred at room temperature for 2 hours under argon. To complete the reaction, additional DMTCI (0.9 g) was added and stirred for another 2 hours. The reaction was quenched with the addition of MeOH (5 ml) and the solvent was evaporated. The residue was dissolved in EtOAc, washed with water, NaHCO3 and brine. After
66 drying over Na2SO4, the EtOAc layer was evaporated and the crude compound was purified on a silica gel column using 3-5% MeOH/CHCI3 as solvent to give pure N4-Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy-β-L-cytidine (2.98 g, 90%) as pale yellow foam. [N4-Benzoyl-5'-O-(dimethoxytrityl)-β-L-2'-deoxycytidine-3'-N,
N-diisopropylcyanoethyl phosphoramidite (3)]
N4-Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy-β-L-cytidine (1.7 g, 2.68 mmol) was dissolved in anhydrous dichloromethane (50 ml), N, N-diisopropylethylamine (1.9 ml, 10.72 mmol) was added under argon followed by 2'-cyanoethyl-N, N-diisopropylchlorophosphoramidite (0.85 ml, 3.5 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated. The residue was dissolved in 80% EtOAc/Et3N (75 ml) and washed with water, NaHCO3 and brine. The organic layer was evaporated and purified on a short silica gel column using a mixture of EtOAc, CH2CI2 and Et3N (30:60: 10) to give
N4-Benzoyl-5'-O-(dimethoxytrityl)-β-L-2'-deoxycytidine-3'-N, N-diisopropylcyanoethyl phosphoramidite (2.06 g, 92%) as a foam.
To a solution of N4-Benzoyl-5'-O-(dimethoxytrityl)-β-L-2'-deoxycytidine-3'-N, N-diisopropylcyanoethyl phosphoramidite (2.06 g, 2.47 mmol) in anhydrous acetonitrile (100 ml),N6-benzoyl-2'-O-acetoxy-β-D-3'-deoxyadenosine (1.08 g, 2.72 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon. To this solution, sublimed 1 H-tetrazole (0.52 g, 7.4 mmol) was added and stirred over night. The solvent was evaporated and the residue was triturated with 70% EtOAc/ether and filtered. The filtrate was evaporated to give
N4-Benzoyl-5'-O-dimethoxytrityl-3,-[O-(2'-O-acetyl)-N6-benzoyl-β-D-3'-deo xy adenosinyl]-2'-deoxy-β-L-cytidine cyanoethyl phosphite ester as a foam
67 and this was used in the next step without further purification.
The dimer N4-Benzoyl-5'-O-dimethoxytrityl-3'-[O-(2'-O-acetyl)-N6-benzoyl-β-D-3'-{deo xyadenosinyl-2'-deoxy-β-L-cytidine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.55 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate. The solvent was evaporated and the residue was dissolved in EtOAc and washed with water, NaHCO3 and brine. EtOAc layer was evaporated and the residue was dissolved in 80% acetic acid/water solution (50 ml) and stirred for 1 hour. Then the solvent was evaporated and the crude product was purified on a silica gel column using 5-10% MeOH/CHCI3 as solvent to give pure compound • (2'-Acetoxy-N6-benzoyl-3'-deoxy-β-D-adenosinyl)-N -Benzoyl-β-L-2'-deoxy citydinyl cyanoethyl phosphate ester (1.46 g) as a foam.
3'-O-(3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxycytidine (6) (L-153) The dimer (2'-Acetoxy-N6-benzoyl-3'-deoxy-β-D-adenosinyl)-N -Benzoyl-β-L-2'-deoxy citydinyl cyanoethyl phosphate ester (1.46 g) was treated with ammoniun hydroxide solution (100 ml) over night. The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH4HCO3 buffer (0.05 - 0.2 M). The pure fractions were collected and lyophillized to give pure 3'-O-(3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxycytidine (L-153) (0.81 g) as white solid.
68 Example16 Synthesis of α-L-dC. Cordvcepin dimer (L-154)
To a solution of α-L-dC (1.6 g, 4.88 mmol) in pyridine (100 ml) was added 4, 4'-dimethoxy trityl chloride (2.43 g, 7.2 mmol) and DMAP (0.13 g, 1.04 mmol) and stirred at room temperature for 2 hours under argon. To complete the reaction, additional DMTCI (1.0 g) was added and stirred for another 2 hours. The reaction was quenched with the addition of MeOH (5 ml) and the solvent was evaporated. The residue was dissolved in EtOAc, washed with water NaHCO3 and brine. After drying over Na2SO4, the EtOAc layer was evaporated and the crude compound was purified on a silica gel column using 3-5% MeOH/CHCI3 as solvent to give pure N4-Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy-α-L-cytidine (2.34 g, 76%) as pale yellow foam.
N -Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy-α-L-cytidine (1.84 g, 2.9 mmol) was dissolved in anhydrous dichloromethane (50 ml). N,
N-diisopropylethylamine (2.0 ml, 11.6 mmol) was added under argon followed by 2'-cyanoethyl-N, N-diisopropylchlorophosphoramidite (0.85 ml, 3.5 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated. The residue was dissolved in 80% EtOAc/Et3N (75 ml) and washed with water, NaHCO3 and brine. The organic layer was evaporated and purified on a short silica gel column using a mixture of EtOAc, hexane and Et3N (50:40:10) to give N4-Benzoyl-5'-O-(dimethoxytrityl)-α-L-2'-deoxycytidine-3'-N, N-diisopropylcyanoethyl phosphoramidite (2.01 g, 83%) as a foam. To a solution of compound
N4-Benzoyl-5'-O-(dimethoxytrityl)-α-L-2'-deoxycytidine-3'-N, N-diisopropylcyanoethyl phosphoramidite (2.01 g, 2.4 mmol) in anhydrous acetonitrile (100 ml),N6-Benzoyl-2'-O-acetoxy-β-D-3'-deoxyadenosine (1.05 g, 2.65 mmol) in acetonitrile (40 ml) was added and stirred for 10
69 minutes under argon. To this solution, sublimed 1 -H-tetrazole (0.5 g, 7.2 mmol) was added and stirred over night. The solvent was evaporated and the residue was triturated with 70% EtOAc/ether and filtered. The filtrate was evaporated to give N4-Benzoyl-5'-O-(dimethoxytrityl)-3'-[O-(2'-acetyl)-N6-Benzoyl-β-D-3'-deox y adenosinyl]-2'-deoxy-α-L-cytidine cyanoethyl phosphite ester as a foam and this was used in the next step without purification.
The dimer N4-Benzoyl-5'-O-(dimethoxytrityl)-3'-[O-(2'-acetyl)-N6-Benzoyl-β-D-3'-deox y adenosinyl]-2'-deoxy-α-L-cytidine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.5 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate. The sulfate was evaporated and the residue was dissolved in EtOAc and washed with water, NaHCO3 and brine. EtOAc layer was evaporated and the residue was dissolved in 80% acetic acid/water solution (50 ml) and stirred for 1 hour. Then the solvent was evaporated and the crude product was purified on a silica gel column using 5-10% MeOH/CHCI3 as solvent to give pure
(2'-Acetoxy-N6-Benzoyl-3'-deoxy-β-D-adenosinyl)-N4-Benzoyl-α-L-2-deoxy citydinyl cyanoethyl phosphate ester (1.8 g) as a foam.
The dimer (2'-Acetoxy-N6-Benzoyl-3'-deoxy-β-D-adenosinyl)-N4-Benzoyl-α-L-2-deoxy citydinyl cyanoethyl phosphate ester (1.8 g) was treated with ammonium hydroxide solution (100 ml) over night, The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH4HCO3 buffer (0.05 - 0.2M). The pure fractions were collected and lyophillized to give pure
70 3'-O-(3'-deoxy-β-D-adenosinyl)-α-L-2'-deoxycytidine (L-154) (1.08 g) as white solid.
Example 17 Synthesis of α-L-dA. Cordvcepin dimer (L-155) To a stirring solution of 2'-deoxy-α-L-adenosine (2.05 g, 8.16 mmol) in pyridine (75 ml) chilled in an ice bath, CISiMe3 (5.17 ml, 40.8 mmol) was added dropwise and stirred for 30 minutes. Benzoyl chloride (4.1 ml, 40.8 mmol) was then added dropwise and the reaction mixture was stirred at room temperature for two hours. This was cooled in an ice bath and 0 water (15 ml) was added dropwise, 15 minutes later concentrated NH4OH
(15 ml) was added to give a solution approximately 2M in ammonia. After 30 minutes the solvent was evaporated and the residue was dissolved in water and washed with ether. The water layer was concentrated and the N6-Benzoyl-2'-deoxy-α-L-adenosine crystallized from water as white solid 5 (2.48 g, 85.8%).
To a solution of compound N6-Benzoyl-2'-deoxy-α-L-adenosine (2.48 g, 6.98 mmol) in pyridine (100 ml) was added 4, 4'-dimethoxy trityl chloride (3.55 g, 10.47 mmol) and DMAP (0.25 g, 2.09 mmol) and stirred at room temperature for 2 hours under argon. To complete the reaction, o additional DMTCI (1.3 g) was added and stirred for another 2 hours. The reaction was quenched with the addition of MeOH (5 ml) and the solvent was evaporated. The residue was dissolved in EtOAc, washed with water, NaHCO3 and brine. After drying over Na2SO4, the EtOAc layer was evaporated and the crude compound was purified on a silica gel column 5 using 3-5% MeOH/CHCI3 as solvent to give pure
N6-Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy-α-L-adenosine (3.42 g, 74.5%) as pale yellow foam.
N6-Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy-α-L-adenosine (1.64
71 g, 2.5 mmol) was dissolved in anhydrous dichloromethane (50 ml). N, N-diisopropylethylamine (1.75 ml, 10.0 mmol) was added under argon followed by 2'-cyanoethyl-N, N-diisopropylchlorophosphoramidite (0.8 ml, 3.25 mmol). The reaction was stirred for 30 minutes and the solvent was evaporated. The residue was dissolved in 80% EtOAc/Et3N (75 ml) and washed with water, NaHCO3 and brine. The organic layer was evaporated and purified on a short silica gel column using a mixture of EtOAc, CH2CI2 and Et3N (40:50:10) to give N6-Benzoyl-5'-O-(dimethoxytrityl)-a-L-2'-deoxyadenosine-3'-N, N-diisopropylcyanoethyl phosphoramidite in quantitative yield.
To a solution of N6-Benzoyl-5'-O-(dimethoxytrityl)-α-L-2'-deoxyadenosine-3'-N, N-diisopropylcyanoethyl phosphoramidite(2.5 mmol) in anhydrous acetonitrile (60 ml), N6-Benzoyl-3'-O-acetoxy-β-D-2'-deoxyadenosine (0.94 g, 2.36 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon. To this solution, sublimed 1 H-tetrazole (0.5 g, 7.2 mmol) was added and stirred overnight. The solvent was evaporated and the residue was triturated with 70% EtOAc/ ether and filtered. The filtrate was evaporated to give N6-Benzoyl-5'-0-dimethoxytrityl-3'-[O-(2'-)-acetyl)-N6-benzoyl-β-D-3'-deoxy adenosinyl]-2'-deoxy-α-L-adenosine cyanoethyl phosphite ester as a foam and this was used in the next step without further purification.
The dimer N6-Benzoyl-5'-0-dimethoxytrityl-3'-[O-(2'-)-acetyl)-N6-benzoyl-β-D-3'-deoxy adenosinyl]-2'-deoxy-α-L-adenosine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.63 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes and the excess iodine was removed by the addition of saturated sodium thiosulfate. The
72 solvent was evaporated the residue was dissolved in EtOAc and washed with water, NaHCO3 and brine. EtOAc layer was evaporated and the residue was dissolved in 80% acetic acid / water solution (50 ml) and stirred for 1 hour. Then the solvent was evaporated and the crude product was purified on a silica gel column using 5-10% MeOH / CHCI3 as solvent to give pure compound
(2'-Acetoxy-N6-benzoyl-3'-deoxy-β-D-adenosinyl)-N6-benzoyl-α-L-2'-deoxy adenosinyl cyanoethyl phosphate ester (0.97 g) as a foam. The dimer (2'-Acetoxy-N6-benzoyl-3'-deoxy-β-D-adenosinyl)-N6-benzoyl-α-L-2'-deoxy adenosinyl cyanoethyl phosphate ester(0.97 g) was treated with ammonium hydroxide solution (100 ml) overnight. The solvent was evaporated and the residue was purified on DEAE Cellulose ion exchange column using gradient of NH4HCO3 buffer (0.05-0.2 M). The pure fractions were collected and lyophillized to give pure {3}
[3']-O-(3'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyadenosine (0.55 g)(L-155) as white solid.
Example 18 Synthesis of β -L-dA. β -D-dA (L-210) To a stirring solution of 2'-deoxy- β -L-adenosine (2.05 g,
8.16 mmol) in pyridine (75 ml) chilled in an ice bath, CISiMe3 (5.17 ml, 40.8 mmol) was added dropwise and stirred for 30 minutes. Benzoyl chloride (4.7 ml, 40.8 mmol) was then added dropwise and the reaction mixture was stirred at room temperature for two hours. This was cooled in an ice bath, and water (15 ml) was added dropwise. 15 minutes later concentrated NH4OH (15 ml) was added to give a solution approximately 2 M in ammonia. After 30 minutes, the solvent was evaporated and the residue was dissolved in water and washed with ether. The water layer
73 was concentrated, and the N6-Benzoyl-2'-deoxy-β-L-adenosine was crystallized from water as white solid (2.48 g, 85.8%).
To a solution of N6-Benzoyl-2'-deoxy-β-L-adenosine(2.48 g, 6.98 mmol) in pyridine (100 ml) was added 4,4'-dimethoxy trityl chloride 5 (3.55 g, 10.47 mmol) and DMPA (0.25 g, 2.09 mmol) and stirred at room temperature for 2 hours under argon. To complete the reaction, additional DMTC1 (1.3 g) was added and stirred for another 2 hours. The reaction was quenched with the addition of MeOH (5 ml), and the solvent was evaporated. The residue was dissolved in EtOAc, washed with water, 0 NaHCO3 and brine. After drying over Na2SO4, the EtOAc layer was evaporated and the crude compound was purified on a silica gel column using 3/5% MeOH/CHC13 as solvent to give pure N6-Benzoyl-5'-O-(di-p-methoxy trityl )-2'-deoxy-β-L-adenosine (3.42 g, 74.5%) as pale yellow foam. 5 N6-Benzoyl-5'-O-(di-p-methoxy trityl)-2'-deoxy-β-L-adenosine(1.71 g, 2.61 mmol) was dissolved in anhydrous dichloromethane (50 ml). N, N-diisopropylethylamine (1.8 ml, 10.34 mmol) was added under argon followed by 2'-cyanoethyl-N,N-diisopropylchlorophosphoramidite (1.0 ml, 4.47 mmol). o The reaction was stirred for 30 minutes, and the solvent was evaporated.
The residue was dissolved in 80% EtOAc/Et3N (75 ml) and washed with water, NaHCO3 and brine. The organic layer was evaporated and purified on a short silica gel column using a mixture of EtOAc, hexane and Et3N (50:40:10) to give 5 N6-Benzoyl-5'-O-(dimethoxytrityl)-β-L-2'-deoxyadenosine-3'-N,N-diisoprop ylcyanoethyl phosphoramidite(1.87 g, 84%) as a foam.
To a solution of N6-Benzoyl-5'-O-(dimethoxytrityl)-β-L-2'-deoxyadenosine-3'-N,N-diisoprop ylcyanoethyl phosphoramidite(1.87 g, 2.18 mmol) in anhydrous
7A acetonitrile (60 ml), N6-Benzoyl-3'-O-acetoxy-β-D-2'-deoxyadenosine (0.95 g, 2.4 mmol) in acetonitrile (40 ml) was added and stirred for 10 minutes under argon. To this solution, sublimed 1 H-tetrazole (0.46 g, 6.6 mmol) was added and stirred overnight. The solvent was evaporated, and the residue was triturated with 70% EtOAc/ether and filtered. The filtrate was evaporated to give
N6-Benzoyl-5'-O-dimethoxytrityl-3'-[O-(3'-O'acetyl)-N6-benzoyl-β-D-2,-deox y adenosinyl]-2'-deoxy-β-L-adenosine cyanoethyl phosphite ester as a foam, and this was used in the next step without further purification. The dimer
N6-Benzoyl-5'-O-dimethoxytrityl-3'-[O-(3'-O'acetyl)-N6-benzoyl-β-D-2'-deox y adenosinyl]-2'-deoxy-β-L-adenosine cyanoethyl phosphite ester was dissolved in THF (24 ml), pyridine (6 ml) and water (0.6 ml). Iodine crystals (0.5 g) were added portion wise until the iodine color persists. The reaction mixture was stirred for another 15 minutes, and the excess iodine was removed by the addition of saturated sodium thiosulfate. The solvent was evaporated, and the residue was dissolved in EtOAc and washed with water, NaHCO3 and brine. EtOAc layer was evaporated, and the residue was dissolved in 80% acetic acid/water solution (50 ml) and stirred for 1 hour. Then the solvent was evaporated, and the crude product was purified on a silica gel column using 5-10% MeOH/CHC13 as solvent to give pure compound
(3'-Acetoxy-N6-benzoyl-2'-deoxy-β-D-adenosinyl)-N6-benzoyl-β-L-2'-deoxy adenosinyl cyanoethyl phosphate ester (0.13 g) as a foam. The dimer
(3'-Acetoxy-N6-benzoyl-2'-deoxy-β-D-adenosinyl)-N6-benzoyl-β-L-2'-deoxy adenosinyl cyanoethyl phosphate ester(1.3 g) was treated with ammonium hydroxide solution (100 ml) overnight. The solvent was evaporated, and the residue was purified on DEAE Cellulose ion exchange column using
75 gradient of NH4HCO3 buffer (0.05-0.2 M). The pure fractions were collected and lyophillized to give pure
3'-O-(2'-deoxy-β-D-adenosinyl)-β-L-2'-deoxyadenosine (L-210) (0.640 g) as white solid.
All patents and publications mentioned in the specifications are indicative of the levels of those skilled in the art to which the invention pertains. All patents and publications are herein incorporated by reference to the same extent as if each individual publication was specifically and individually indicated to be incorporated by reference. One skilled in the art readily appreciates that the patent invention is well adapted to carry out the objectives and obtain the ends and advantages mentioned as well as those inherent therein. Dimers, pharmaceutical compositions, treatments, methods, procedures and techniques described herein are presently representative of the preferred embodiments and are intended to be exemplary and are not intended as limitations of the scope. Changes therein and other uses will occur those skilled in the art which are encompassed within the spirit of the invention or defined by the scope of the pending claims.
76

Claims

What is claimed is:
1. A method for treating a viral infection, a bacterial infection, a fungal infection, cancer, or a parasitic infection, in a mammal comprising administering to said mammal a compound having the formula:
H╬╕-<t . Rt
Figure imgf000079_0002
Figure imgf000079_0001
OH
HOΓÇö ^╬╕ O R2
I , II , III or a pharmaceutically acceptable salt thereof, wherein:
B1 and B2 are each selected from the group consisting of ╬▓-D, ╬▓-L and ╬▒-L nucleosides and wherein at least one of B1 or B2 must be a L nucleoside;
R and R2 are purine or pyrimidine bases; and wherein R and R2 are the same or a different base and wherein when B or B2 is attached to the intemucleotide binding agent (IBA) and said B^ or B2 is a L nucleoside, then the R or R2 attached to said base cannot be cytosine; and
IBA is selected from the linking groups consisting of phosphodiester, phosphorothioate, methoxy phosphotriesters, methylphosphonates,
77 phosphorodithioates, phosphorothioates, silyl ethers, sulphonates and ethylenedioxy ethers.
2. The method of Claim 1 wherein said compound is selected from the group consisting of 3'-O-(╬▒-L-5-fluoro-2'-deoxyuridinyl)-╬▓-D-5-fluoro-2'-deoxyuridine, (L-102), 3'-O-(╬▓-D-5-fluoro-2'-deoxyuridinyl)-╬▒-L-5-fluoro-2'-deoxyuridine, (L-103), 3'-O-(╬▓-D-5-fluoro-2'-deoxyuridinyl)-╬▒-L-2'-deoxyuridine, (L-107), 3'-O-(╬▒-L-5-fluoro-2'-deoxyuridinyl)-╬▒-L-5-fluoro-2'-deoxyuridine, (L-108), 3'-O-(╬▓-L-5-fluoro-2'-deoxyuridinyl)-╬▓-L-5-fluoro-2'-deoxyuridine, (L-109), 3'-O-(╬▓-D-5-fluoro-2'-deoxyuridinyl)-╬▓-L-5-fluoro-2'-deoxyuridine, (L-110), 3'-O-(╬▓-D-5-fluoro-2'-deoxyuridinyl)-╬▒-L-2'-deoxycytidine, (L-111 ), 3'-O-(╬▓-D-5-fluoro-2'-deoxyuridinyl)-2'-deoxy-╬▓-L-cytidine (L-113), 3'-O-(2'-deoxy-╬▓-L-cytidinyl)-╬▓-D-5-fluoro-2'-deoxyuridine (L-114), 3'-O-(2'-deoxy-╬▒-L-cytidinyl)-╬▓-D-5-fluoro-2'-deoxyuridine (L-115), 3 '-O-(╬▓-D-5-fluoro-2'-deoxyuridinyl)-╬▓-L-2 '-deoxvuridine (L-117), 3'-O-(╬▓-L-5-fluoro-2'-deoxyuridinyl)-╬▒-L-5-fluoro-2'-deoxyuridine (L-119), 3'-O-(╬▓-D-5-fluoro-2'-deoxyuridinyl)-╬▒-L-5-fluoro-2'-deoxyuridine (3', 3') (L-122), 3'-O-(3'-deoxy-╬▓-D-adenosinyl)-╬▓-L-2'-deoxyuridine (L-150), 3'-O-(3'-deoxy-╬▓-D-adenosinyl)-╬▓-L-2'-deoxyadenosine (L-151 ), 3'-O-(3'-deoxy-╬▓-D-adenosinyl)-╬▒-L-2'-deoxyuridine (L-152), 3'-O-(3'-deoxy-╬▓-D-adenosinyl)-╬▓-L-2'-deoxycytidine (L-153), 3'-O-(3'-deoxy-╬▓-D-adenosinyl)-╬▒-L-2'-deoxycytidine (L-154), 3'-O-(3'-deoxy-╬▓-D-adenosinyl)-╬▓-L-2'-deoxyadenosine (L-155), 3'-O-(2'-deoxy-╬▓-D-adenosinyl)-╬▓-L-2'-deoxyadenosine (L-210), or a therapeutically acceptable salt thereof.
3. The method of Claim 1 wherein the formula is I, B1 is ╬▓-D, B2 is ╬▒-L, R., and R2 are both 5 FUdR, and IBA is a phosphodiester.
78
4. The method of Claim 1 wherein the formula is II, B is ╬▒-L, B2 is ╬▓-D, R1 and R2 are both 5-FUdR, and IBA is a phosphodiester.
5. The method of Claim 1 wherein the compound is 3'-O-(╬▓-D-5-fluoro-2'-deoxyuridinyl)-╬▒-L-5-fluoro-2'-deoxyuridine, (L-103).
6. The method of Claim 1 wherein IBA is a phosphodiester linking group.
7. A compound having the formula:
X O
Figure imgf000081_0001
Figure imgf000081_0002
or a pharmaceutically acceptable salt thereof, wherein R1 is -CH2OH in the L- configuration; wherein R2 and R3 are selected from the group consisting of -H and -OH; and wherein X is a nitrogenous base consisting of purines and pyrimidines.
8. The compound of Claim 7 wherein R2 and R3 are each -OH, and wherein X is adenine.
9. The compound of Claim 8 wherein R3 is oriented equatorially, wherein R2 is axially oriented, and wherein adenine is axially oriented.
79
10. The compound of Claim 7 wherein R2 is -OH and R3 is -H, and wherein X is 5-fluorouracil.
11. The compound of Claim 10 wherein R2 is oriented axially, and wherein 5'-fluorouracil is oriented axially.
12. The compound of Claim 7 wherein R2 and R3 are each -OH, and wherein X is guanine.
13. The compound of Claim 12 wherein R2 and R3 are each oriented axially, and wherein guanine is oriented equatorially.
14. The compound of Claim 7 wherein R2 and R3 are each -OH, and wherein X is adenine.
15. The compound of Claim 14 wherein R2 and R3 are each oriented axially, and wherein adenine is oriented equatorially.
16. The compound of Claim 7 wherein R2 and R3 are each -OH, and wherein X is inine.
17. The compound of Claim 16 wherein R2 and R3 are each oriented axially, and wherein inine is oriented equatorially.
18. The compound of Claim 7 wherein R2 and R3 are each -OH, and wherein X is mercaptoguanine.
19. The compound of Claim 18 wherein R2 and R3 are each oriented axially, and wherein mercaptoguanine is oriented equatorially.
80
20. The compound of Claim 7 wherein R2 is -OH and R1 is -H, and wherein X is adenine.
21. The compound of Claim 20 wherein R2 is oriented axially, and wherein adenine is oriented equatorially.
22. The compound of Claim 7 wherein R2 is -OH and R^ is -H, and wherein X is deoxyinine.
23. The compound of Claim 22 wherein R2 is oriented axially, and wherein deoxyinosine is attached to the ╬▓ hydrogen on the ribose ring.
24. The compound of Claim 7 wherein R2 is -OH and R3 is -OH, and wherein X is adenine.
25. The compound of Claim 24 wherein R2 and R3 are each oriented axially, and wherein adenine is oriented axially.
26. The compound of Claim 7 wherein R2 is -OH and R3 is -H, and wherein X is 3-aminopyrine, and further wherein the point of attachment of said aminopurine to the ribose ring is hydrogen 3.
27. The compound of Claim 26 wherein R2 is oriented axially, and wherein aminopurine is oriented axially.
28. The compound of Claim 7 wherein R2 is -OH and R3 is -H, and wherein X is guanine.
29. The compound of Claim 28 wherein R2 is oriented axially, and
81 wherein guanine is oriented equatorially.
30. The compound of Claim 7 wherein R2 and R3 are each -H, and wherein X is adenine.
31. The compound of Claim 30 wherein adenine is oriented equatorially.
32. The compound of Claim 7 wherein R2 and R3 are each -H, and wherein X is adenine.
33. The compound of Claim 32 wherein adenine is oriented axially.
34. The compound of Claim 7 wherein R2 and R3 are each -OH, and wherein X is 6-thiopurine.
35. The compound of Claim 34 wherein R2 and R3 are each axially oriented and 6-thiopurine is oriented equatorially.
36. The compound of Claim 7 wherein R2 is -OH and R3 is -H, and wherein X is 5-fluorouracil.
37. The compound of Claim 36 wherein R2 is equatorially oriented, and wherein the 5-fluorouracil is attached to the ╬▒ hydrogen on the ribose ring.
38. The compound of Claim 7 wherein R2 and R3 are each -OH, and wherein X is 5-fluorouracil.
39. The compound of Claim 38 wherein R2 is oriented axially, and
82 wherein 5'-fluorouracil oriented axially.
40. The nucleoside dimer having the formula:
R, ΓÇö X ΓÇö R2
wherein X is a moiety suitable for chemically linking R., and R2; wherein R^ and R2 are nucleosides; and wherein R^ and R2 are attached to X through -OH groups.
41. The compound of Claim 40 wherein X is selected from the group consisting of PO4 and S=PO3.
42. The compound according to Claim 40 wherein R is ╬▓-D-deoxyfluorouridine.
43. The compound according to Claim 40 wherein R is ╬▒-L-deoxyfluorouridine.
44. The compound according to Claim 40 wherein R is ╬▓-L-deoxyfluorouridine.
45. The compound according to Claim 40 wherein R., is ╬▒-L-deoxycytosine.
46. The compound according to Claim 40 wherein R is ╬▓-L-deoxycytosine.
83
47. The compound according to Claim 40 wherein R1 is ╬▓-L-deoxyuridine.
48. The compound according to Claim 40 wherein R., is ╬▓-L-deoxyguanosine.
49. The compound according to Claim 40 wherein R1 is ╬▓-L-deoxyadenosine.
50. The compound according to Claim 40 wherein R., is ╬▒-L-deoxyadenosine.
51. The compound according to Claim 40 wherein R is nitrobenzylthionosine.
52. The nucleoside dimer comprising: ╬▓-D-deoxyfluorouridine, ╬▓-L-adenosine, and a suitable moiety for linking the two said nucleosides.
53. Nitrobenzylthionosine.
54. The compound having the non-stereospecific formula:
Figure imgf000086_0001
wherein R1 and R2 are each either (CH3COSCH2CH2O)2P=0
84 or -H; and wherein X is a purine or pyrimidine.
55. The compound of Claim 54 wherein R, is (CH3COSCH2CH2O)2P=0, wherein R2 is -H, wherein -OR! is oriented equatorially, wherein -OR2 is oriented axially, and wherein -X is oriented axially.
56. The compound of Claim 54 wherein R is -H, wherein R2 is (CH3COSCH2CH2O)2P=0, wherein -OR! is oriented equatorially, wherein -OR2 is oriented axially, and wherein -X is oriented axially.
57. The compound of Claim 54 wherein R^ and R2 are each (CH3COSCH2CH2O)2P=0, wherein -OR, is oriented equatorially, wherein -OR2 is oriented axially, and wherein -X is oriented axially.
58. The compound of Claim 54 wherein R^ is -H, wherein R2 is (CH3COSCH2CH2O)2P=0, wherein -OR, is oriented axially, wherein -OR2 is oriented equatorially, and wherein -X is oriented equatorially.
59. The compound of Claim 54 wherein R., and R2 are each (CH3COSCH2CH2O)2P=0, wherein -OR! is oriented axially, wherein -OR2 is oriented equatorially, and wherein -X is oriented equatorially.
60. The compound of Claim 54 wherein R^ is -H, wherein R2 is (CH3COSCH2CH2O)2P=0, wherein -OR! is oriented axially, wherein -OR2 is oriented equatorially, and wherein -X is oriented axially.
61. The compound of Claim 54 wherein R! and R2 are each (CH3COSCH2CH2O)2P=0, wherein -O^ is oriented axially, wherein -OR2
85 is oriented equatorially, and wherein -X is oriented axially.
62. A compound having the formula R! ΓÇö X ΓÇö R2; wherein R! is selected from the group consisting of purines and pyrimidines; wherein R2 is (CH3COSCH2CH2O)2P=0; and wherein X is a suitable linking group.
63. A compound having the formula R! ΓÇö X ΓÇö R2; wherein Ri is selected from the group consisting of purines and pyrimidines; wherein R2 is selected from the group consisting of purines and pyrimidines; and wherein X is a suitable linking group.
64. A method for treating a [parasitic infection, other than a] Plasmodium falciparum infection, [a bacterial infection, a viral infection, a fungal infection, or cancer] in a mammal comprising administering to an afflicted mammal a therapeutic dose of the compound of claims 7-63.
65. A method for treating a [parasitic infection, other than a] Plasmodium falciparum infection[, a bacterial infection, a viral infection, a fungal infection, or cancer] in a mammal comprising administering to said mammal a therapeutically effective amount of the compound having the formula:
R! ΓÇö X ΓÇö R2
wherein X a moiety suitable for chemically linking R! and R2;
86 wherein R! and R2 are nucleosides; and wherein R! and R2 are attached to X through -OH groups.
66. The method of Claim 64 wherein X is selected from the group consisting of PO4 and S=PO3.
67. The method according to Claims 64 or 65 wherein Ri is ╬▓-D-deoxyfluorouridine.
68. The method according to Claims 64 or 65 wherein R1 is ╬▒-L-deoxyfluorouridine.
69. The method according to Claims 64 or 65 wherein R., is ╬▓-L-deoxyfluorouridine.
70. The method according to Claims 64 or 65 wherein R is ╬▒-L-deoxycytosine.
71. The method according to Claims 64 or 65 wherein R is ╬▓-L-deoxycytosine.
72. The method according to Claims 64 or 65 wherein R, is ╬▓-L-deoxyuridine.
73. The method according to Claims 64 or 65 wherein R is ╬▓-L-deoxyguanosine.
74. The method according to Claims 64 or 65 wherein R^ is ╬▓-L-deoxyadenosine.
87
75. The method according to Claims 64 or 65 wherein R is ╬▒-L-deoxyadenosine.
76. The method according to Claims 64 or 65 wherein R.. is nitrobenzylthionosine.
77. A method for treating a disease in a mammal comprising administering to an afflicted mammal a therapeutically effective dose of a deoxyadenosine or a dideoxyadenosine.
78. The method of claim 77 wherein said disease is cancer.
79. The method of claim 78 wherein said disease is malaria.
80. The method of claim 79 wherein said disease is caused by viral infection.
81. The method of claim 79 wherein said disease is caused by a bacterial infection.
82. The method of claim 79 wherein said disease is caused by a parasitic infection.
83. The method of claim 79 wherein said disease is caused by a fungal infection.]
88
PCT/US1999/005360 1998-03-11 1999-03-11 Novel nucleoside analogs and uses in treating disease WO1999045935A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2000535350A JP2002506036A (en) 1998-03-11 1999-03-11 Novel nucleoside analogs and their use in treating diseases
EP99912434A EP1069903A1 (en) 1998-03-11 1999-03-11 Novel nucleoside analogs and uses in treating disease
CA002322494A CA2322494A1 (en) 1998-03-11 1999-03-11 Novel nucleoside analogs and uses in treating disease
AU30808/99A AU3080899A (en) 1998-03-11 1999-03-11 Novel nucleoside analogs and uses in treating disease

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/038,647 1998-03-11
US09/038,647 US5939402A (en) 1995-09-21 1998-03-11 Nucleoside analogs and uses against parasitic infection
US09/219,947 1998-12-23
US09/220,307 1998-12-23
US09/219,947 US6242428B1 (en) 1995-09-21 1998-12-23 Nucleoside analogs and uses in treating Plasmodium falciparum infection
US09/220,307 US6207649B1 (en) 1995-09-21 1998-12-23 Nucleoside analogs and uses in treating disease

Publications (1)

Publication Number Publication Date
WO1999045935A1 true WO1999045935A1 (en) 1999-09-16

Family

ID=27365434

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/005360 WO1999045935A1 (en) 1998-03-11 1999-03-11 Novel nucleoside analogs and uses in treating disease

Country Status (5)

Country Link
EP (1) EP1069903A1 (en)
JP (1) JP2002506036A (en)
AU (1) AU3080899A (en)
CA (1) CA2322494A1 (en)
WO (1) WO1999045935A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009531A3 (en) * 1998-08-10 2000-06-15 Norivio Pharmaceuticals Ltd β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
EP1701952A1 (en) * 2004-01-08 2006-09-20 Medivir Aktiebolag Dutpase inhibitors
US7323451B2 (en) 2002-08-06 2008-01-29 Idenix Pharmaceuticals, Inc. Crystalline and amorphous forms of beta-L-2′-deoxythymidine
US7585851B2 (en) 2000-06-15 2009-09-08 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
US7795238B2 (en) 1998-08-10 2010-09-14 Idenix Pharmaceuticals, Inc. β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
WO2015181624A3 (en) * 2014-05-28 2016-03-31 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
CN106459127A (en) * 2014-05-28 2017-02-22 艾登尼克斯药业有限公司 Nucleoside derivatives for the treatment of cancer

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004201286B2 (en) * 1998-08-10 2007-06-21 Centre National De La Recherche Scientifique (Cnrs) Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
AU2007216721B2 (en) * 1998-08-10 2011-05-19 Centre National De La Recherche Scientifique Beta-L-2'-Deoxy Nucleosides for the Treatment of Hepatitis B
AU2004209986C1 (en) * 2003-02-03 2009-08-13 Gilead Palo Alto, Inc. Partial and full agonists of A1 adenosine receptors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5672594A (en) * 1994-10-24 1997-09-30 Genencor International, Inc. L-erythrosyl nucleosides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559101A (en) * 1994-10-24 1996-09-24 Genencor International, Inc. L-ribofuranosyl nucleosides
US5672594A (en) * 1994-10-24 1997-09-30 Genencor International, Inc. L-erythrosyl nucleosides

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795238B2 (en) 1998-08-10 2010-09-14 Idenix Pharmaceuticals, Inc. β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
US6395716B1 (en) 1998-08-10 2002-05-28 Novirio Pharmaceuticals Limited β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
US9290533B2 (en) 1998-08-10 2016-03-22 Novartis Ag β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
US7304043B2 (en) 1998-08-10 2007-12-04 Idenix Pharmaceuticals, Inc. β-L-2′-deoxy-nucleosides for the treatment of hepatitis B
WO2000009531A3 (en) * 1998-08-10 2000-06-15 Norivio Pharmaceuticals Ltd β-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B
US7585851B2 (en) 2000-06-15 2009-09-08 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
WO2003084975A1 (en) * 2002-04-10 2003-10-16 Grünenthal GmbH New analogs of nitrobenzylthioinosine
US7358235B2 (en) 2002-04-10 2008-04-15 Gruenenthal Gmbh Analogs of nitrobenzylthioinosine
US7323451B2 (en) 2002-08-06 2008-01-29 Idenix Pharmaceuticals, Inc. Crystalline and amorphous forms of beta-L-2′-deoxythymidine
US7589079B2 (en) 2002-08-06 2009-09-15 Novartis Ag Crystalline and amorphous forms of beta-L-2′-deoxythymidine
US7858594B2 (en) 2002-08-06 2010-12-28 Novartis Pharma Ag Crystalline and amorphous forms of beta-L-2′-deoxythymidine
EP1701952A1 (en) * 2004-01-08 2006-09-20 Medivir Aktiebolag Dutpase inhibitors
WO2015181624A3 (en) * 2014-05-28 2016-03-31 Idenix Pharmaceuticals, Inc Nucleoside derivatives for the treatment of cancer
CN106459127A (en) * 2014-05-28 2017-02-22 艾登尼克斯药业有限公司 Nucleoside derivatives for the treatment of cancer

Also Published As

Publication number Publication date
EP1069903A1 (en) 2001-01-24
AU3080899A (en) 1999-09-27
JP2002506036A (en) 2002-02-26
CA2322494A1 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
US5939402A (en) Nucleoside analogs and uses against parasitic infection
US10968248B2 (en) Trinucleotide mRNA cap analogs
EP0980377B1 (en) Anti-viral pyrimidine nucleoside analogues
US5457187A (en) Oligonucleotides containing 5-fluorouracil
CA1333390C (en) Fluorinated nucleosides and process for treating retrovirus infections therewith
EP1280813B1 (en) Anti-viral pyrimidine nucleoside analogues
US20040132684A1 (en) Polymeric nucleoside prodrugs
EP1113020B1 (en) Nucleosides and oligonucleotides containing boron clusters
WO2004080466A1 (en) Cytidine analogs and methods of use
EP1069903A1 (en) Novel nucleoside analogs and uses in treating disease
US20120149888A1 (en) Synthesis of ara-2&#39;-o-methyl-nucleosides, corresponding phosphoramidites and oligonucleotides incorporating novel modifications for biological application in therapeuctics, diagnostics, g- tetrad forming oligonucleotides and aptamers
US20180251485A1 (en) Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
Urata et al. Design and racemic synthesis of conformationally restricted carbocyclic pyrimidine nucleoside analogs based on the structure of the L-nucleoside residue in heterochiral DNA
Gorovits et al. Innovative Design and Synthesis of Antiparasitic Agents
MXPA99009965A (en) Anti-viral pyrimidine nucleoside analogues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2322494

Country of ref document: CA

Ref country code: CA

Ref document number: 2322494

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 30808/99

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 535350

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999912434

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999912434

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999912434

Country of ref document: EP